<?xml version="1.0" encoding="UTF-8"?>
<OAI-PMH xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
  <responseDate>2024-05-03T03:54:33Z</responseDate>
  <request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:6222943" metadataPrefix="pmc">https:/www.ncbi.nlm.nih.gov/pmc/oai/oai.cgi</request>
  <GetRecord>
    <record>
      <header>
        <identifier>oai:pubmedcentral.nih.gov:6222943</identifier>
        <datestamp>2018-11-19</datestamp>
        <setSpec>jaha</setSpec>
        <setSpec>pmc-open</setSpec>
      </header>
      <metadata>
        <article xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.3/ https://jats.nlm.nih.gov/archiving/1.3/xsd/JATS-archivearticle1-3.xsd" article-type="research-article">
          <front>
            <journal-meta>
              <journal-id journal-id-type="nlm-ta">J Am Heart Assoc</journal-id>
              <journal-id journal-id-type="iso-abbrev">J Am Heart Assoc</journal-id>
              <journal-id journal-id-type="doi">10.1002/(ISSN)2047-9980</journal-id>
              <journal-id journal-id-type="publisher-id">JAH3</journal-id>
              <journal-id journal-id-type="hwp">ahaoa</journal-id>
              <journal-title-group>
                <journal-title>Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease</journal-title>
              </journal-title-group>
              <issn pub-type="epub">2047-9980</issn>
              <publisher>
                <publisher-name>John Wiley and Sons Inc.</publisher-name>
                <publisher-loc>Hoboken</publisher-loc>
              </publisher>
            </journal-meta>
            <article-meta>
              <article-id pub-id-type="accession">PMC6222943</article-id>
              <article-id pub-id-type="pmcid">PMC6222943</article-id>
              <article-id pub-id-type="pmc-uid">6222943</article-id>
              <article-id pub-id-type="pmid">30371182</article-id>
              <article-id pub-id-type="pmid">30371182</article-id>
              <article-id pub-id-type="doi">10.1161/JAHA.118.009326</article-id>
              <article-id pub-id-type="publisher-id">JAH33491</article-id>
              <article-categories>
                <subj-group subj-group-type="overline">
                  <subject>Original Research</subject>
                </subj-group>
                <subj-group subj-group-type="heading">
                  <subject>Original Research</subject>
                  <subj-group subj-group-type="heading">
                    <subject>Hypertension</subject>
                  </subj-group>
                </subj-group>
              </article-categories>
              <title-group>
                <article-title>Effects of Intensive Systolic Blood Pressure Lowering on Cardiovascular Events and Mortality in Patients With Type 2 Diabetes Mellitus on Standard Glycemic Control and in Those Without Diabetes Mellitus: Reconciling Results From <styled-content style="fixed-case">ACCORD BP</styled-content> and <styled-content style="fixed-case">SPRINT</styled-content>
</article-title>
                <alt-title alt-title-type="left-running-head">Beddhu et al</alt-title>
              </title-group>
              <contrib-group>
                <contrib id="jah33491-cr-0001" contrib-type="author" corresp="yes">
                  <name>
                    <surname>Beddhu</surname>
                    <given-names>Srinivasan</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <address>
                    <email>srinivasan.beddhu@hsc.utah.edu</email>
                  </address>
                  <xref ref-type="aff" rid="jah33491-aff-0001">
                    <sup>1</sup>
                  </xref>
                  <xref ref-type="aff" rid="jah33491-aff-0002">
                    <sup>2</sup>
                  </xref>
                </contrib>
                <contrib id="jah33491-cr-0002" contrib-type="author">
                  <name>
                    <surname>Chertow</surname>
                    <given-names>Glenn M.</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <xref ref-type="aff" rid="jah33491-aff-0005">
                    <sup>5</sup>
                  </xref>
                </contrib>
                <contrib id="jah33491-cr-0003" contrib-type="author">
                  <name>
                    <surname>Greene</surname>
                    <given-names>Tom</given-names>
                  </name>
                  <degrees>PhD</degrees>
                  <xref ref-type="aff" rid="jah33491-aff-0003">
                    <sup>3</sup>
                  </xref>
                </contrib>
                <contrib id="jah33491-cr-0004" contrib-type="author">
                  <name>
                    <surname>Whelton</surname>
                    <given-names>Paul K.</given-names>
                  </name>
                  <degrees>MB, MD, MSc</degrees>
                  <xref ref-type="aff" rid="jah33491-aff-0006">
                    <sup>6</sup>
                  </xref>
                </contrib>
                <contrib id="jah33491-cr-0005" contrib-type="author">
                  <name>
                    <surname>Ambrosius</surname>
                    <given-names>Walter T.</given-names>
                  </name>
                  <degrees>PhD</degrees>
                  <xref ref-type="aff" rid="jah33491-aff-0007">
                    <sup>7</sup>
                  </xref>
                </contrib>
                <contrib id="jah33491-cr-0006" contrib-type="author">
                  <name>
                    <surname>Cheung</surname>
                    <given-names>Alfred K.</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <xref ref-type="aff" rid="jah33491-aff-0001">
                    <sup>1</sup>
                  </xref>
                  <xref ref-type="aff" rid="jah33491-aff-0002">
                    <sup>2</sup>
                  </xref>
                </contrib>
                <contrib id="jah33491-cr-0007" contrib-type="author">
                  <name>
                    <surname>Cutler</surname>
                    <given-names>Jeffrey</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <xref ref-type="aff" rid="jah33491-aff-0008">
                    <sup>8</sup>
                  </xref>
                </contrib>
                <contrib id="jah33491-cr-0008" contrib-type="author">
                  <name>
                    <surname>Fine</surname>
                    <given-names>Lawrence</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <xref ref-type="aff" rid="jah33491-aff-0008">
                    <sup>8</sup>
                  </xref>
                </contrib>
                <contrib id="jah33491-cr-0009" contrib-type="author">
                  <name>
                    <surname>Boucher</surname>
                    <given-names>Robert</given-names>
                  </name>
                  <degrees>BS</degrees>
                  <xref ref-type="aff" rid="jah33491-aff-0002">
                    <sup>2</sup>
                  </xref>
                </contrib>
                <contrib id="jah33491-cr-0010" contrib-type="author">
                  <name>
                    <surname>Wei</surname>
                    <given-names>Guo</given-names>
                  </name>
                  <degrees>MS</degrees>
                  <xref ref-type="aff" rid="jah33491-aff-0002">
                    <sup>2</sup>
                  </xref>
                  <xref ref-type="aff" rid="jah33491-aff-0003">
                    <sup>3</sup>
                  </xref>
                </contrib>
                <contrib id="jah33491-cr-0011" contrib-type="author">
                  <name>
                    <surname>Zhang</surname>
                    <given-names>Chong</given-names>
                  </name>
                  <degrees>MS</degrees>
                  <xref ref-type="aff" rid="jah33491-aff-0003">
                    <sup>3</sup>
                  </xref>
                </contrib>
                <contrib id="jah33491-cr-0012" contrib-type="author">
                  <name>
                    <surname>Kramer</surname>
                    <given-names>Holly</given-names>
                  </name>
                  <degrees>MD, MPH</degrees>
                  <xref ref-type="aff" rid="jah33491-aff-0009">
                    <sup>9</sup>
                  </xref>
                  <xref ref-type="aff" rid="jah33491-aff-0010">
                    <sup>10</sup>
                  </xref>
                </contrib>
                <contrib id="jah33491-cr-0013" contrib-type="author">
                  <name>
                    <surname>Bress</surname>
                    <given-names>Adam P.</given-names>
                  </name>
                  <degrees>PharmD, MS</degrees>
                  <xref ref-type="aff" rid="jah33491-aff-0004">
                    <sup>4</sup>
                  </xref>
                </contrib>
                <contrib id="jah33491-cr-0014" contrib-type="author">
                  <name>
                    <surname>Kimmel</surname>
                    <given-names>Paul L.</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <xref ref-type="aff" rid="jah33491-aff-0011">
                    <sup>11</sup>
                  </xref>
                </contrib>
                <contrib id="jah33491-cr-0015" contrib-type="author">
                  <name>
                    <surname>Oparil</surname>
                    <given-names>Suzanne</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <xref ref-type="aff" rid="jah33491-aff-0012">
                    <sup>12</sup>
                  </xref>
                </contrib>
                <contrib id="jah33491-cr-0016" contrib-type="author">
                  <name>
                    <surname>Lewis</surname>
                    <given-names>Cora E.</given-names>
                  </name>
                  <degrees>MD, MSPH</degrees>
                  <xref ref-type="aff" rid="jah33491-aff-0013">
                    <sup>13</sup>
                  </xref>
                </contrib>
                <contrib id="jah33491-cr-0017" contrib-type="author">
                  <name>
                    <surname>Rahman</surname>
                    <given-names>Mahboob</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <xref ref-type="aff" rid="jah33491-aff-0014">
                    <sup>14</sup>
                  </xref>
                </contrib>
                <contrib id="jah33491-cr-0018" contrib-type="author">
                  <name>
                    <surname>Cushman</surname>
                    <given-names>William C.</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <xref ref-type="aff" rid="jah33491-aff-0015">
                    <sup>15</sup>
                  </xref>
                </contrib>
              </contrib-group>
              <aff id="jah33491-aff-0001">
                <label>
                  <sup>1</sup>
                </label>
                <named-content content-type="organisation-division">Medical Service</named-content>
                <institution>Veterans Affairs Salt Lake City Health Care System</institution>
                <named-content content-type="city">Salt Lake City</named-content>
                <country>UT</country>
              </aff>
              <aff id="jah33491-aff-0002">
                <label>
                  <sup>2</sup>
                </label>
                <named-content content-type="organisation-division">Division of Nephrology &amp; Hypertension</named-content>
                <institution>University of Utah School of Medicine</institution>
                <named-content content-type="city">Salt Lake City</named-content>
                <named-content content-type="country-part">UT</named-content>
              </aff>
              <aff id="jah33491-aff-0003">
                <label>
                  <sup>3</sup>
                </label>
                <named-content content-type="organisation-division">Division of Biostatistics</named-content>
                <institution>University of Utah School of Medicine</institution>
                <named-content content-type="city">Salt Lake City</named-content>
                <named-content content-type="country-part">UT</named-content>
              </aff>
              <aff id="jah33491-aff-0004">
                <label>
                  <sup>4</sup>
                </label>
                <named-content content-type="organisation-division">Division of Health System Innovation and Research</named-content>
                <named-content content-type="organisation-division">Department of Population Health Sciences</named-content>
                <institution>University of Utah School of Medicine</institution>
                <named-content content-type="city">Salt Lake City</named-content>
                <named-content content-type="country-part">UT</named-content>
              </aff>
              <aff id="jah33491-aff-0005">
                <label>
                  <sup>5</sup>
                </label>
                <named-content content-type="organisation-division">Division of Nephrology</named-content>
                <institution>Stanford University School of Medicine</institution>
                <named-content content-type="city">Palo Alto</named-content>
                <named-content content-type="country-part">CA</named-content>
              </aff>
              <aff id="jah33491-aff-0006">
                <label>
                  <sup>6</sup>
                </label>
                <institution>Tulane University School of Public Health and Tropical Medicine</institution>
                <named-content content-type="city">New Orleans</named-content>
                <named-content content-type="country-part">LA</named-content>
              </aff>
              <aff id="jah33491-aff-0007">
                <label>
                  <sup>7</sup>
                </label>
                <named-content content-type="organisation-division">Department of Biostatistical Sciences</named-content>
                <institution>Wake Forest School of Medicine</institution>
                <named-content content-type="city">Winston‐Salem</named-content>
                <named-content content-type="country-part">NC</named-content>
              </aff>
              <aff id="jah33491-aff-0008">
                <label>
                  <sup>8</sup>
                </label>
                <institution>National Heart, Lung and Blood Institute</institution>
                <named-content content-type="city">Bethesda</named-content>
                <named-content content-type="country-part">MD</named-content>
              </aff>
              <aff id="jah33491-aff-0009">
                <label>
                  <sup>9</sup>
                </label>
                <named-content content-type="organisation-division">Division of Nephrology and Hypertension</named-content>
                <named-content content-type="organisation-division">Departments of Public Health Sciences and Medicine</named-content>
                <institution>Loyola University Chicago</institution>
                <named-content content-type="city">Maywood</named-content>
                <named-content content-type="country-part">IL</named-content>
              </aff>
              <aff id="jah33491-aff-0010">
                <label>
                  <sup>10</sup>
                </label>
                <institution>Hines Veteran's Affairs Medical Center</institution>
                <named-content content-type="city">Hines</named-content>
                <named-content content-type="country-part">IL</named-content>
              </aff>
              <aff id="jah33491-aff-0011">
                <label>
                  <sup>11</sup>
                </label>
                <institution>National Institute of Diabetes, Digestive and Kidney Diseases</institution>
                <named-content content-type="city">Bethesda</named-content>
                <named-content content-type="country-part">MD</named-content>
              </aff>
              <aff id="jah33491-aff-0012">
                <label>
                  <sup>12</sup>
                </label>
                <named-content content-type="organisation-division">Division of Cardiovascular Disease</named-content>
                <named-content content-type="organisation-division">Department of Medicine</named-content>
                <institution>University of Alabama at Birmingham</institution>
                <named-content content-type="country-part">AL</named-content>
              </aff>
              <aff id="jah33491-aff-0013">
                <label>
                  <sup>13</sup>
                </label>
                <institution>Department of Epidemiology, School of Public Health</institution>
                <named-content content-type="city">University of Alabama at Birmingham</named-content>
                <named-content content-type="country-part">AL</named-content>
              </aff>
              <aff id="jah33491-aff-0014">
                <label>
                  <sup>14</sup>
                </label>
                <institution>Case Western Reserve University</institution>
                <named-content content-type="city">Cleveland</named-content>
                <named-content content-type="country-part">OH</named-content>
              </aff>
              <aff id="jah33491-aff-0015">
                <label>
                  <sup>15</sup>
                </label>
                <institution>Veterans Affairs Medical Center</institution>
                <named-content content-type="city">Memphis</named-content>
                <named-content content-type="country-part">TN</named-content>
              </aff>
              <author-notes>
                <corresp id="correspondenceTo"><label>*</label><bold>Correspondence to:</bold> Srinivasan Beddhu, MD, 85 North Medical Drive East, Room 201, Salt Lake City, UT 84112. E‐mail: <email>srinivasan.beddhu@hsc.utah.edu</email></corresp>
              </author-notes>
              <pub-date pub-type="epub">
                <day>18</day>
                <month>9</month>
                <year>2018</year>
              </pub-date>
              <pub-date pub-type="collection">
                <day>18</day>
                <month>9</month>
                <year>2018</year>
              </pub-date>
              <volume>7</volume>
              <issue>18</issue>
              <issue-id pub-id-type="doi">10.1002/jah3.2018.7.issue-18</issue-id>
              <elocation-id>e009326</elocation-id>
              <history>
                <date date-type="received">
                  <day>29</day>
                  <month>3</month>
                  <year>2018</year>
                </date>
                <date date-type="accepted">
                  <day>25</day>
                  <month>7</month>
                  <year>2018</year>
                </date>
              </history>
              <permissions>
                <!--<copyright-statement content-type="issue-copyright"> Copyright &#x000a9; 2018 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley Blackwell <copyright-statement>-->
                <copyright-statement content-type="article-copyright">© 2018 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley.</copyright-statement>
                <license license-type="creativeCommonsBy-nc-nd">
                  <license-p>This is an open access article under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc-nd/4.0/">http://creativecommons.org/licenses/by-nc-nd/4.0/</ext-link> License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.</license-p>
                </license>
              </permissions>
              <self-uri content-type="pdf" xlink:type="simple" xlink:href="file:JAH3-7-e009326.pdf"/>
              <abstract id="jah33491-abs-0001">
                <sec id="jah33491-sec-0001">
                  <title>Background</title>
                  <p>Intensive systolic blood pressure (<styled-content style="fixed-case">SBP</styled-content>) lowering significantly reduced cardiovascular disease (<styled-content style="fixed-case">CVD</styled-content>) events in SPRINT (Systolic Blood Pressure Intervention Trial) but not in ACCORD BP (Action to Control Cardiovascular Risk in Diabetes Blood Pressure).</p>
                </sec>
                <sec id="jah33491-sec-0002">
                  <title>Methods and Results</title>
                  <p><styled-content style="fixed-case">SPRINT</styled-content> tested the effects of intensive (&lt;120 mm Hg) versus standard (&lt;140 mm Hg) <styled-content style="fixed-case">SBP</styled-content> goals on <styled-content style="fixed-case">CVD</styled-content> events and all‐cause mortality. Using 2×2 factorial design, <styled-content style="fixed-case">ACCORD BP</styled-content> tested the same <styled-content style="fixed-case">SBP</styled-content> intervention in addition to an intensive versus standard glycemia intervention. We compared the effects of intensive <styled-content style="fixed-case">SBP</styled-content> lowering on the composite <styled-content style="fixed-case">CVD</styled-content> end point and all‐cause mortality in <styled-content style="fixed-case">SPRINT</styled-content> with its effects within each of the glycemia arms in <styled-content style="fixed-case">ACCORD BP</styled-content>. Intensive <styled-content style="fixed-case">SBP</styled-content> lowering decreased the hazard of the composite <styled-content style="fixed-case">CVD</styled-content> end point similarly in <styled-content style="fixed-case">SPRINT</styled-content> (hazard ratio: 0.75; 95% confidence interval, 0.64–0.89) and in the <styled-content style="fixed-case">ACCORD BP</styled-content> standard glycemia arm (hazard ratio: 0.77; 95% confidence interval, 0.63–0.95; interaction <italic>P</italic>=0.87). However, the effect of intensive <styled-content style="fixed-case">SBP</styled-content> lowering on the composite <styled-content style="fixed-case">CVD</styled-content> end point in the <styled-content style="fixed-case">ACCORD BP</styled-content> intensive glycemia arm (hazard ratio: 1.04; 95% confidence interval, 0.83–1.29) was significantly different from <styled-content style="fixed-case">SPRINT</styled-content> (interaction <italic>P</italic>=0.023). Patterns were similar for all‐cause mortality.</p>
                </sec>
                <sec id="jah33491-sec-0003">
                  <title>Conclusions</title>
                  <p>The effects of intensive <styled-content style="fixed-case">SBP</styled-content> control on <styled-content style="fixed-case">CVD</styled-content> events and all‐cause mortality were similar in patients without diabetes mellitus and in those with diabetes mellitus on standard glycemic control. An interaction between intensive <styled-content style="fixed-case">SBP</styled-content> lowering and intensive glycemic control may have masked beneficial effects of intensive <styled-content style="fixed-case">SBP</styled-content> lowering in <styled-content style="fixed-case">ACCORD BP</styled-content>.</p>
                </sec>
                <sec id="jah33491-sec-0004">
                  <title>Clinical Trial Registration</title>
                  <p><styled-content style="fixed-case">URL</styled-content>: <ext-link ext-link-type="uri" xlink:href="http://www.clinicaltrials.gov">http://www.clinicaltrials.gov</ext-link>. Unique identifiers: <styled-content style="fixed-case">NCT</styled-content>01206062, <styled-content style="fixed-case">NCT</styled-content>00000620.</p>
                </sec>
              </abstract>
              <kwd-group kwd-group-type="author-generated">
                <kwd id="jah33491-kwd-0001">cardiovascular outcomes</kwd>
                <kwd id="jah33491-kwd-0002">diabetes mellitus</kwd>
                <kwd id="jah33491-kwd-0003">high blood pressure</kwd>
                <kwd id="jah33491-kwd-0004">hypertension</kwd>
              </kwd-group>
              <kwd-group kwd-group-type="subject-categories">
                <title>Subject Categories</title>
                <kwd>Hypertension</kwd>
              </kwd-group>
              <funding-group>
                <award-group>
                  <funding-source>National Institute of Diabetes and Digestive and Kidney Diseases</funding-source>
                  <award-id>R01 DK091437</award-id>
                  <award-id>R21 DK106574</award-id>
                </award-group>
                <award-group>
                  <funding-source>University of Utah Study Design and Biostatistics Center</funding-source>
                </award-group>
                <award-group>
                  <funding-source>National Center for Research Resources</funding-source>
                  <award-id>UL1‐RR025764</award-id>
                  <award-id>C06‐RR11234</award-id>
                </award-group>
                <award-group>
                  <funding-source>National Institutes of Health</funding-source>
                </award-group>
                <award-group>
                  <funding-source>National Heart, Lung, and Blood Institute</funding-source>
                </award-group>
                <award-group>
                  <funding-source>National Institute on Aging</funding-source>
                </award-group>
                <award-group>
                  <funding-source>National Institute of Neurological Disorders and Stroke</funding-source>
                  <award-id>HHSN268200900040C</award-id>
                  <award-id>HHSN268200900046C</award-id>
                  <award-id>HHSN268200900047C</award-id>
                  <award-id>HHSN268200900048C</award-id>
                  <award-id>HHSN268200900049C</award-id>
                </award-group>
                <award-group>
                  <funding-source>Department of Veterans Affairs</funding-source>
                </award-group>
                <award-group>
                  <funding-source>NCATS</funding-source>
                </award-group>
                <award-group>
                  <funding-source>CWRU</funding-source>
                  <award-id>UL1TR000439</award-id>
                </award-group>
                <award-group>
                  <funding-source>OSU</funding-source>
                  <award-id>UL1RR025755</award-id>
                </award-group>
                <award-group>
                  <funding-source>U Penn</funding-source>
                  <award-id>UL1RR024134</award-id>
                  <award-id>UL1TR000003</award-id>
                </award-group>
                <award-group>
                  <funding-source>Boston</funding-source>
                  <award-id>UL1RR025771</award-id>
                </award-group>
                <award-group>
                  <funding-source>Stanford</funding-source>
                  <award-id>UL1TR000093</award-id>
                </award-group>
                <award-group>
                  <funding-source>Tufts</funding-source>
                  <award-id>UL1RR025752</award-id>
                  <award-id>UL1TR000073</award-id>
                  <award-id>UL1TR001064</award-id>
                </award-group>
                <award-group>
                  <funding-source>University of Illinois</funding-source>
                  <award-id>UL1TR000050</award-id>
                </award-group>
                <award-group>
                  <funding-source>University of Pittsburgh</funding-source>
                  <award-id>UL1TR000005</award-id>
                </award-group>
                <award-group>
                  <funding-source>UT Southwestern</funding-source>
                  <award-id>9U54TR000017‐06</award-id>
                </award-group>
                <award-group>
                  <funding-source>University of Utah</funding-source>
                  <award-id>UL1TR000105‐05</award-id>
                </award-group>
                <award-group>
                  <funding-source>Vanderbilt University</funding-source>
                  <award-id>UL1 TR000445</award-id>
                </award-group>
                <award-group>
                  <funding-source>George Washington University</funding-source>
                  <award-id>UL1TR000075</award-id>
                </award-group>
                <award-group>
                  <funding-source>University of CA, Davis</funding-source>
                  <award-id>UL1 TR000002</award-id>
                </award-group>
                <award-group>
                  <funding-source>University of Florida</funding-source>
                  <award-id>UL1 TR000064</award-id>
                </award-group>
                <award-group>
                  <funding-source>University of Michigan</funding-source>
                  <award-id>UL1TR000433</award-id>
                </award-group>
                <award-group>
                  <funding-source>Tulane University</funding-source>
                  <award-id>P30GM103337</award-id>
                </award-group>
              </funding-group>
              <counts>
                <fig-count count="8"/>
                <table-count count="2"/>
                <page-count count="14"/>
                <word-count count="7519"/>
              </counts>
              <custom-meta-group>
                <custom-meta>
                  <meta-name>source-schema-version-number</meta-name>
                  <meta-value>2.0</meta-value>
                </custom-meta>
                <custom-meta>
                  <meta-name>component-id</meta-name>
                  <meta-value>jah33491</meta-value>
                </custom-meta>
                <custom-meta>
                  <meta-name>cover-date</meta-name>
                  <meta-value>18 September 2018</meta-value>
                </custom-meta>
                <custom-meta>
                  <meta-name>details-of-publishers-convertor</meta-name>
                  <meta-value>Converter:WILEY_ML3GV2_TO_NLMPMC version:version=5.4.7.1 mode:remove_FC converted:18.09.2018</meta-value>
                </custom-meta>
              </custom-meta-group>
            </article-meta>
            <notes>
              <p content-type="self-citation">
                <mixed-citation publication-type="journal" id="jah33491-cit-1001">(<source xml:lang="en">J Am Heart Assoc</source>. <year>2018</year>;<volume>7</volume>:<elocation-id>e009326</elocation-id> DOI: <pub-id pub-id-type="doi">10.1161/JAHA.118.009326</pub-id>.)<pub-id pub-id-type="pmid">30371182</pub-id></mixed-citation>
              </p>
            </notes>
          </front>
          <body>
            <p>
              <boxed-text position="anchor" content-type="box" id="jah33491-blkfxd-0001" orientation="portrait">
                <sec id="jah33491-sec-0006">
                  <title>Clinical Perspective</title>
                  <sec id="jah33491-sec-0007">
                    <title>What Is New?</title>
                    <p>
                      <list list-type="bullet" id="jah33491-list-0001">
                        <list-item>
                          <p>Previous data showed that intensive systolic blood pressure lowering compared with standard systolic blood pressure control (goal &lt;120 versus &lt;140 mm Hg) was beneficial in patients without diabetes mellitus in SPRINT (Systolic Blood Pressure Intervention Trial) but not in those with type 2 diabetes mellitus in ACCORD BP (Action to Control Cardiovascular Risk in Diabetes Blood Pressure).</p>
                        </list-item>
                        <list-item>
                          <p>The results of the current analyses show that intensive systolic blood pressure lowering decreased the risk of cardiovascular disease events and all‐cause mortality similarly in SPRINT participants and ACCORD BP participants on standard glycemic control but not in ACCORD BP participants on intensive glycemic control.</p>
                        </list-item>
                      </list>
                    </p>
                  </sec>
                  <sec id="jah33491-sec-0008">
                    <title>What Are the Clinical Implications?</title>
                    <p>
                      <list list-type="bullet" id="jah33491-list-0002">
                        <list-item>
                          <p>These findings support the current American College of Cardiology and American Heart Association guidelines of a systolic blood pressure goal of &lt;130 mm Hg in patients both with and without type 2 diabetes mellitus.</p>
                        </list-item>
                      </list>
                    </p>
                  </sec>
                </sec>
              </boxed-text>
            </p>
            <sec id="jah33491-sec-0009">
              <p>Beginning in the 1960s, randomized controlled trials demonstrated the value of treating high diastolic blood pressure and, subsequently, high systolic blood pressure (SBP).<xref rid="jah33491-bib-0001" ref-type="ref">1</xref>, <xref rid="jah33491-bib-0002" ref-type="ref">2</xref> However, the treatment target for SBP has been uncertain.<xref rid="jah33491-bib-0003" ref-type="ref">3</xref>, <xref rid="jah33491-bib-0004" ref-type="ref">4</xref> Several recent meta‐analyses support “intensive” SBP lowering in patients with and without diabetes mellitus, but these included randomized controlled trials that targeted a higher SBP goal (&lt;140 mm Hg or even higher) for “intensive” SBP control or blood pressure medication trials that did not have a predefined SBP goal.<xref rid="jah33491-bib-0002" ref-type="ref">2</xref>, <xref rid="jah33491-bib-0005" ref-type="ref">5</xref>, <xref rid="jah33491-bib-0006" ref-type="ref">6</xref>, <xref rid="jah33491-bib-0007" ref-type="ref">7</xref> The recent American College of Cardiology/American Heart Association guidelines recommend an SBP goal of &lt;130 mm Hg in patients with and without diabetes mellitus.<xref rid="jah33491-bib-0008" ref-type="ref">8</xref>
</p>
              <p>Whether the SBP goal should be even lower, particularly &lt;120 mm Hg, could be debated. Two large randomized controlled trials sponsored by the National Institutes of Health (NIH) tested an SBP goal of &lt;120 mm Hg. Both studies compared the effects of intensive (SBP target &lt;120 mm Hg) and standard (SBP target &lt;140 mm Hg) SBP treatment targets on cardiovascular disease (CVD) events. The first of these trials was ACCORD BP (Action to Control Cardiovascular Risk in Diabetes Blood Pressure) in patients with type 2 diabetes mellitus (T2DM).<xref rid="jah33491-bib-0009" ref-type="ref">9</xref> In addition to intensive versus standard SBP targets, in a 2×2 factorial design, ACCORD BP also tested intensive versus standard glycemic targets (glycated hemoglobin &lt;6% versus 7.0–7.9%).<xref rid="jah33491-bib-0009" ref-type="ref">9</xref> In the primary analysis that combined the intensive and standard glycemia arms, ACCORD BP showed a nonsignificant 12% decrease in the primary composite CVD end point, along with a nonsignificant 7% increase in all‐cause mortality for the SBP intervention.<xref rid="jah33491-bib-0009" ref-type="ref">9</xref>
</p>
              <p>In SPRINT (Systolic Blood Pressure Intervention Trial), which tested the same SBP targets in patients without diabetes mellitus,<xref rid="jah33491-bib-0010" ref-type="ref">10</xref>, <xref rid="jah33491-bib-0011" ref-type="ref">11</xref> the BP intervention was stopped early because intensive SBP lowering resulted in a substantial reduction in both the primary composite CVD end point and all‐cause mortality.</p>
              <p>Reasons for these discrepant findings remain widely debated. Because ACCORD BP had fewer participants than SPRINT<xref rid="jah33491-bib-0009" ref-type="ref">9</xref>, <xref rid="jah33491-bib-0011" ref-type="ref">11</xref> and the observed event rate was half the event rate assumed for power calculations in ACCORD BP,<xref rid="jah33491-bib-0009" ref-type="ref">9</xref> it has been suggested that ACCORD BP was underpowered.<xref rid="jah33491-bib-0012" ref-type="ref">12</xref> Nonetheless, despite the smaller sample size, the reported number of events and event rates in ACCORD BP<xref rid="jah33491-bib-0009" ref-type="ref">9</xref> were higher than in SPRINT. ACCORD BP reported an interaction <italic>P</italic> value of 0.08 for comparison of the effects of intensive SBP control on the primary composite CVD end point in the standard glycemia versus intensive glycemia arms.<xref rid="jah33491-bib-0009" ref-type="ref">9</xref> Another ACCORD BP report noted that compared with the combined standard SBP and standard glycemia group, intensive management of either SBP or glycemia alone improved major CVD outcomes.<xref rid="jah33491-bib-0013" ref-type="ref">13</xref> These findings raise the possibility that potential interactions between the intensive glycemia and SBP interventions in ACCORD BP might have masked beneficial effects of the SBP intervention.</p>
              <p>In this study, we compared the effects of intensive SBP lowering on the composite CVD end point and all‐cause mortality in SPRINT with its effects within each of the glycemia arms in ACCORD BP. We hypothesized that an interaction between the ACCORD BP glycemic and SBP interventions masked the potential beneficial effects of intensive SBP lowering in ACCORD BP. Furthermore, we investigated whether the effects of the intensive SBP intervention changed following early discontinuation of the intensive glycemia intervention in ACCORD BP.</p>
            </sec>
            <sec id="jah33491-sec-0010">
              <title>Methods</title>
              <p>Limited data from the SPRINT and ACCORD BP data sets are available from National Heart, Lung, and Blood Institute (NHLBI) data repository<xref rid="jah33491-bib-0014" ref-type="ref">14</xref> for reproducing or replicating the results of this analysis. The Statistical Analysis section provides details of analytical procedures.</p>
              <p>The current study was based on a secondary analysis of the limited‐access SPRINT BioLINCC data set obtained from the NIH and direct analyses of the ACCORD BP database. The SPRINT and ACCORD BP studies were approved by the institutional review board at each participating study site. All participants provided written informed consent.</p>
              <sec id="jah33491-sec-0011">
                <title>Action to Control Cardiovascular Risk in Diabetes Blood Pressure</title>
                <p>Details of the study population, interventions, and study procedures for ACCORD BP are provided in the supplement and published elsewhere.<xref rid="jah33491-bib-0015" ref-type="ref">15</xref> In brief, ACCORD was a randomized controlled trial sponsored by the NHLBI to simultaneously examine the effects of glycemic control, SBP control, and treatment with fenofibrate on a background of statin on CVD outcomes in 10 251 participants aged ≥40 years with T2DM at high risk for CVD events and a glycated hemoglobin level ≥7.5%.<xref rid="jah33491-bib-0016" ref-type="ref">16</xref> Using a double 2×2 factorial design, all 10 251 participants were randomly assigned to intensive (HbA1c [hemoglobin A1c] target &lt;6.0%) or standard (HbA1c target 7.0–7.9%) glycemic therapy.<xref rid="jah33491-bib-0016" ref-type="ref">16</xref> In addition, 4733 of the trial participants were randomly assigned to intensive (target &lt;120 mm Hg) or standard SBP‐lowering therapy (target &lt;140 mm Hg; ACCORD BP trial).<xref rid="jah33491-bib-0009" ref-type="ref">9</xref> Another 5518 participants were randomly assigned to receive fenofibrate or placebo on a background of simvastatin<xref rid="jah33491-bib-0017" ref-type="ref">17</xref> (ACCORD Lipid trial). The current analysis was based on participants in the ACCORD BP trial.</p>
              </sec>
              <sec id="jah33491-sec-0012">
                <title>ACCORD BP Intervention and Follow‐up</title>
                <p>Eligible participants were randomly assigned to either intensive or standard SBP control, stratified by clinical site. Details of the ACCORD BP measurement and intervention algorithm are provided in the supplement. In brief, participants in the intensive SBP group were seen at least once a month for 4 months, with additional monthly visits if needed for titration to their SBP goal, and every 2 months thereafter; participants in the standard SBP group were scheduled at months 1 and 4 and every 4 months thereafter.</p>
              </sec>
              <sec id="jah33491-sec-0013">
                <title>Systolic Blood Pressure Intervention Trial</title>
                <p>SPRINT participants were recruited between November 2010 and March 2013. Adults aged ≥50 years with SBP 130 to 180 mm Hg and high CVD risk were recruited. A major exclusion criterion was presence of diabetes mellitus. Further details of SPRINT inclusion and exclusion criteria were published elsewhere and are provided in the supplement.<xref rid="jah33491-bib-0010" ref-type="ref">10</xref>, <xref rid="jah33491-bib-0011" ref-type="ref">11</xref>
</p>
              </sec>
              <sec id="jah33491-sec-0014">
                <title>SPRINT SBP Intervention and Follow‐up</title>
                <p>Participants in both arms were seen monthly for the first 3 months and every 3 months thereafter. Additional monthly visits could be scheduled for drug titration to meet the assigned SBP goal. Blood pressure measurement and SBP goals were similar to those used in the ACCORD BP trial.<xref rid="jah33491-bib-0010" ref-type="ref">10</xref>, <xref rid="jah33491-bib-0011" ref-type="ref">11</xref> A decision to stop the SPRINT intervention was made August 20, 2015, because of beneficial effects of the intensive SBP reduction.<xref rid="jah33491-bib-0011" ref-type="ref">11</xref> Only events and follow‐up time that occurred on or before August 20, 2015, were included in this analysis.</p>
              </sec>
              <sec id="jah33491-sec-0015">
                <title>Definition of CVD Outcomes</title>
                <p>The primary end point in SPRINT was a composite of nonfatal myocardial infarction, acute coronary syndrome not resulting in myocardial infarction, stroke, acute decompensated heart failure, or death from CVD causes. The primary CVD end point in ACCORD BP was similar to that of SPRINT except that it did not include acute decompensated heart failure or acute coronary syndrome. To match the SPRINT experience as closely as possible, we defined a modified composite CVD end point in ACCORD BP as a composite of the primary ACCORD BP CVD end point or congestive heart failure or unstable angina. In sensitivity analyses, we compared the SPRINT‐protocol‐defined<xref rid="jah33491-bib-0018" ref-type="ref">18</xref> primary composite CVD end point in SPRINT participants with the ACCORD BP–protocol‐defined<xref rid="jah33491-bib-0015" ref-type="ref">15</xref> primary composite CVD end point in each of the glycemia arms in ACCORD BP.</p>
              </sec>
              <sec id="jah33491-sec-0016">
                <title>Statistical Analysis</title>
                <p>We compared patient characteristics and outcomes between the intensive SBP and standard SBP groups for the 9361 SPRINT participants, the 2362 ACCORD BP participants who were randomized to the standard glycemia arm, and the 2371 ACCORD BP participants who were randomized to the intensive glycemia arm. We summarized baseline participant characteristics by SBP group separately within each cohort. We present mean SBP with 95% confidence intervals (CIs) in the intensive and standard SBP groups for each cohorts at baseline and at each follow‐up visit.</p>
                <p>We used time‐to‐event methods to evaluate the effects of the SBP intervention on the composite CVD end points and all‐cause mortality in each cohort and to provide pairwise comparison of the effects of the SBP intervention across the 3 cohorts and between SPRINT and ACCORD BP after pooling across the 2 glycemia arms. Our primary analyses censored follow‐up at the last outcome event ascertainment, with event rates expressed as number of events per patient‐year. We used Kaplan–Meier curves to depict the cumulative incidence of the composite CVD end points and all‐cause mortality over follow‐up. We applied Cox proportional hazards regression analyses to estimate hazard ratios (HRs) between the groups with intensive and standard SBP goals. We combined all 3 cohorts into a single analysis and performed Cox regression with stratification of the baseline hazard by study cohort and by clinical site in SPRINT and by clinical center network in ACCORD BP. The Cox models were parameterized to estimate separate HRs within each cohort and a pooled HR across the 2 glycemia control interventions of ACCORD BP. Comparisons among these HRs to evaluate interactions between the SBP intervention and the 3 cohorts were performed using likelihood ratio tests. These comparisons were repeated after censoring the follow‐up of the ACCORD BP patients at the termination of the glycemia intervention when this occurred before the patient's last outcome ascertainment. In sensitivity analyses, the Cox regressions comparing randomized SBP groups were repeated in the ACCORD BP participants using the ACCORD BP–protocol‐defined primary composite CVD end point.</p>
                <p>In addition to these analyses, which compared participants according to their randomized treatment assignment, we applied time‐dependent Cox regression in the intensive glycemia arm of ACCORD BP to compare the HR for current exposure to the intensive versus standard SBP intervention before and after the early discontinuation of the glycemia intervention on February 5, 2008.</p>
                <p>We also present Kaplan–Meier curves for the cumulative incidence of the composite CVD end point and all‐cause death within the 2 SBP groups following the discontinuation of the glycemia intervention, with time 0 reset to the discontinuation date.</p>
                <p>In addition, we performed a sensitivity analysis to compare the HR for the intensive versus standard SBP intervention in the first 14 months following initial randomization to the HR for the 14 months after discontinuation of the glycemia intervention in the intensive glycemia arm in ACCORD BP.</p>
                <p>We performed all analyses in SAS v9.4 (SAS Institute) and R v3.4.3 (R Foundation for Statistical Computing). We used a 2‐sided α=0.05 for hypothesis tests, without adjustment for multiple comparisons.</p>
              </sec>
            </sec>
            <sec id="jah33491-sec-0017">
              <title>Results</title>
              <p>The current analysis included 9361 SPRINT participants and 4733 ACCORD BP participants (Figure <xref rid="jah33491-sup-0001" ref-type="supplementary-material">S1</xref>). Baseline demographic, clinical, and laboratory characteristics were similar in the intensive and standard SBP groups within SPRINT and within both ACCORD BP glycemia arms (Table <xref rid="jah33491-tbl-0001" ref-type="table">1</xref>). However, compared with the SPRINT participants, the ACCORD BP participants were younger, more often female, and had higher mean body mass index, mean estimated glomerular filtration rate, and median value of albuminuria (Table <xref rid="jah33491-sup-0001" ref-type="supplementary-material">S1</xref>). Baseline blood pressure and number of antihypertensive medications were similar in both studies.</p>
              <table-wrap id="jah33491-tbl-0001" xml:lang="en" orientation="portrait" position="float">
                <label>Table 1</label>
                <caption>
                  <p>Baseline Characteristics by SBP Groups in SPRINT (n=9361) and ACCORD‐BP Standard (n=2362) and Intensive Glycemia (n=2371) Arms<xref ref-type="fn" rid="jah33491-note-0003">a</xref>
</p>
                </caption>
                <table frame="hsides" rules="groups">
                  <col style="border-right:solid 1px #000000" span="1"/>
                  <col style="border-right:solid 1px #000000" span="1"/>
                  <col style="border-right:solid 1px #000000" span="1"/>
                  <col style="border-right:solid 1px #000000" span="1"/>
                  <col style="border-right:solid 1px #000000" span="1"/>
                  <col style="border-right:solid 1px #000000" span="1"/>
                  <col style="border-right:solid 1px #000000" span="1"/>
                  <thead valign="top">
                    <tr style="border-bottom:solid 1px #000000">
                      <th align="left" rowspan="4" valign="top" colspan="1"/>
                      <th align="left" colspan="2" style="border-bottom:solid 1px #000000" valign="top" rowspan="1">SPRINT</th>
                      <th align="left" colspan="4" style="border-bottom:solid 1px #000000" valign="top" rowspan="1">ACCORD‐BP</th>
                    </tr>
                    <tr style="border-bottom:solid 1px #000000">
                      <th align="left" rowspan="2" valign="top" colspan="1">Standard SBP</th>
                      <th align="left" rowspan="2" valign="top" colspan="1">Intensive SBP</th>
                      <th align="left" colspan="2" style="border-bottom:solid 1px #000000" valign="top" rowspan="1">Standard Glycemia</th>
                      <th align="left" colspan="2" style="border-bottom:solid 1px #000000" valign="top" rowspan="1">Intensive Glycemia</th>
                    </tr>
                    <tr style="border-bottom:solid 1px #000000">
                      <th align="left" style="border-bottom:solid 1px #000000" valign="top" rowspan="1" colspan="1">Standard SBP</th>
                      <th align="left" style="border-bottom:solid 1px #000000" valign="top" rowspan="1" colspan="1">Intensive SBP</th>
                      <th align="left" style="border-bottom:solid 1px #000000" valign="top" rowspan="1" colspan="1">Standard SBP</th>
                      <th align="left" style="border-bottom:solid 1px #000000" valign="top" rowspan="1" colspan="1">Intensive SBP</th>
                    </tr>
                    <tr style="border-bottom:solid 1px #000000">
                      <th align="left" valign="top" rowspan="1" colspan="1">n=4683</th>
                      <th align="left" valign="top" rowspan="1" colspan="1">n=4678</th>
                      <th align="left" valign="top" rowspan="1" colspan="1">n=1178</th>
                      <th align="left" valign="top" rowspan="1" colspan="1">n=1184</th>
                      <th align="left" valign="top" rowspan="1" colspan="1">n=1193</th>
                      <th align="left" valign="top" rowspan="1" colspan="1">n=1178</th>
                    </tr>
                  </thead>
                  <tbody>
                    <tr>
                      <td align="left" rowspan="1" colspan="1">Age, y</td>
                      <td align="left" rowspan="1" colspan="1">67.9±9.5</td>
                      <td align="left" rowspan="1" colspan="1">67.9±9.4</td>
                      <td align="left" rowspan="1" colspan="1">62.7±6.7</td>
                      <td align="left" rowspan="1" colspan="1">62.8±6.8</td>
                      <td align="left" rowspan="1" colspan="1">62.8±6.8</td>
                      <td align="left" rowspan="1" colspan="1">62.6±6.4</td>
                    </tr>
                    <tr>
                      <td align="left" rowspan="1" colspan="1">Female sex, %</td>
                      <td align="left" rowspan="1" colspan="1">35.2</td>
                      <td align="left" rowspan="1" colspan="1">36.0</td>
                      <td align="left" rowspan="1" colspan="1">47.1</td>
                      <td align="left" rowspan="1" colspan="1">46.9</td>
                      <td align="left" rowspan="1" colspan="1">48.2</td>
                      <td align="left" rowspan="1" colspan="1">48.6</td>
                    </tr>
                    <tr>
                      <td align="left" rowspan="1" colspan="1">White race, %</td>
                      <td align="left" rowspan="1" colspan="1">57.7</td>
                      <td align="left" rowspan="1" colspan="1">57.7</td>
                      <td align="left" rowspan="1" colspan="1">59.5</td>
                      <td align="left" rowspan="1" colspan="1">58.7</td>
                      <td align="left" rowspan="1" colspan="1">55.9</td>
                      <td align="left" rowspan="1" colspan="1">61.0</td>
                    </tr>
                    <tr>
                      <td align="left" rowspan="1" colspan="1">Never smoked, %</td>
                      <td align="left" rowspan="1" colspan="1">44.2</td>
                      <td align="left" rowspan="1" colspan="1">43.8</td>
                      <td align="left" rowspan="1" colspan="1">45.4</td>
                      <td align="left" rowspan="1" colspan="1">45.9</td>
                      <td align="left" rowspan="1" colspan="1">44.8</td>
                      <td align="left" rowspan="1" colspan="1">43.4</td>
                    </tr>
                    <tr>
                      <td align="left" rowspan="1" colspan="1">SBP, mm Hg</td>
                      <td align="left" rowspan="1" colspan="1">140±15</td>
                      <td align="left" rowspan="1" colspan="1">140±16</td>
                      <td align="left" rowspan="1" colspan="1">140±15</td>
                      <td align="left" rowspan="1" colspan="1">138±16</td>
                      <td align="left" rowspan="1" colspan="1">139±15</td>
                      <td align="left" rowspan="1" colspan="1">139±16</td>
                    </tr>
                    <tr>
                      <td align="left" rowspan="1" colspan="1">DBP, mm Hg</td>
                      <td align="left" rowspan="1" colspan="1">78±12</td>
                      <td align="left" rowspan="1" colspan="1">78±12</td>
                      <td align="left" rowspan="1" colspan="1">76±10</td>
                      <td align="left" rowspan="1" colspan="1">76±10</td>
                      <td align="left" rowspan="1" colspan="1">76±10</td>
                      <td align="left" rowspan="1" colspan="1">76±10</td>
                    </tr>
                    <tr>
                      <td align="left" rowspan="1" colspan="1">Clinical atherosclerotic disease, %<xref ref-type="fn" rid="jah33491-note-0004">b</xref>
</td>
                      <td align="left" rowspan="1" colspan="1">20.0</td>
                      <td align="left" rowspan="1" colspan="1">20.0</td>
                      <td align="left" rowspan="1" colspan="1">33.3</td>
                      <td align="left" rowspan="1" colspan="1">33.0</td>
                      <td align="left" rowspan="1" colspan="1">33.4</td>
                      <td align="left" rowspan="1" colspan="1">35.1</td>
                    </tr>
                    <tr>
                      <td align="left" rowspan="1" colspan="1">Antihypertensive agents (no./patient)</td>
                      <td align="left" rowspan="1" colspan="1">1.8±1.0</td>
                      <td align="left" rowspan="1" colspan="1">1.8±1.0</td>
                      <td align="left" rowspan="1" colspan="1">1.7±1.1</td>
                      <td align="left" rowspan="1" colspan="1">1.7±1.2</td>
                      <td align="left" rowspan="1" colspan="1">1.6±1.1</td>
                      <td align="left" rowspan="1" colspan="1">1.7±1.1</td>
                    </tr>
                    <tr>
                      <td align="left" rowspan="1" colspan="1">Duration of diabetes mellitus</td>
                      <td align="left" rowspan="1" colspan="1">NA</td>
                      <td align="left" rowspan="1" colspan="1">NA</td>
                      <td align="left" rowspan="1" colspan="1">9.0 (5.0, 15.0)</td>
                      <td align="left" rowspan="1" colspan="1">9.0 (5.0, 15.0)</td>
                      <td align="left" rowspan="1" colspan="1">10.0 (5.0, 16.0)</td>
                      <td align="left" rowspan="1" colspan="1">9.0 (5.0, 15.0)</td>
                    </tr>
                    <tr>
                      <td align="left" rowspan="1" colspan="1">Glycated hemoglobin%</td>
                      <td align="left" rowspan="1" colspan="1">Not reported</td>
                      <td align="left" rowspan="1" colspan="1">Not reported</td>
                      <td align="left" rowspan="1" colspan="1">8.3±1.0</td>
                      <td align="left" rowspan="1" colspan="1">8.3±1.0</td>
                      <td align="left" rowspan="1" colspan="1">8.3±1.0</td>
                      <td align="left" rowspan="1" colspan="1">8.3±1.0</td>
                    </tr>
                    <tr>
                      <td align="left" rowspan="1" colspan="1">Fasting plasma glucose, mg/dL</td>
                      <td align="left" rowspan="1" colspan="1">99±13</td>
                      <td align="left" rowspan="1" colspan="1">99±14</td>
                      <td align="left" rowspan="1" colspan="1">173±55</td>
                      <td align="left" rowspan="1" colspan="1">175±55</td>
                      <td align="left" rowspan="1" colspan="1">172±54</td>
                      <td align="left" rowspan="1" colspan="1">175±55</td>
                    </tr>
                    <tr>
                      <td align="left" rowspan="1" colspan="1">BMI, kg/m<sup>2</sup>
</td>
                      <td align="left" rowspan="1" colspan="1">29.8±5.7</td>
                      <td align="left" rowspan="1" colspan="1">29.9±5.8</td>
                      <td align="left" rowspan="1" colspan="1">32.1±5.2</td>
                      <td align="left" rowspan="1" colspan="1">32.3±5.6</td>
                      <td align="left" rowspan="1" colspan="1">32.1±5.5</td>
                      <td align="left" rowspan="1" colspan="1">32.1±5.6</td>
                    </tr>
                    <tr>
                      <td align="left" rowspan="1" colspan="1">Estimated MDRD GFR, mL/min/1.73 m<sup>2</sup>
</td>
                      <td align="left" rowspan="1" colspan="1">72±21</td>
                      <td align="left" rowspan="1" colspan="1">72±21</td>
                      <td align="left" rowspan="1" colspan="1">91±23</td>
                      <td align="left" rowspan="1" colspan="1">91±23</td>
                      <td align="left" rowspan="1" colspan="1">91±24</td>
                      <td align="left" rowspan="1" colspan="1">90±24</td>
                    </tr>
                    <tr>
                      <td align="left" rowspan="1" colspan="1">Urine albumin creatinine ratio, mg/g</td>
                      <td align="left" rowspan="1" colspan="1">9.4 (5.6, 21.8)</td>
                      <td align="left" rowspan="1" colspan="1">9.6 (5.7, 21.1)</td>
                      <td align="left" rowspan="1" colspan="1">16.0 (7.0, 56.0)</td>
                      <td align="left" rowspan="1" colspan="1">15.0 (7.0, 45.0)</td>
                      <td align="left" rowspan="1" colspan="1">14.0 (7.0, 42.0)</td>
                      <td align="left" rowspan="1" colspan="1">15.0 (7.0, 46.0)</td>
                    </tr>
                  </tbody>
                </table>
                <table-wrap-foot>
                  <fn id="jah33491-note-0002">
                    <p>Percentages are reported for categorical variables and mean±SD or median (25th, 75th percentiles) for continuous variables. ACCORD BP indicates Action to Control Cardiovascular Risk in Diabetes Blood Pressure; BMI, body mass index; DBP, diastolic blood pressure; GFR, glomerular filtration rate; MDRD, Modification of Diet in Renal Disease; NA, not assessed; SBP, systolic blood pressure; SPRINT, Systolic Blood Pressure Intervention Trial.</p>
                  </fn>
                  <fn id="jah33491-note-0003">
                    <label>a</label>
                    <p>All <italic>P</italic> values of comparison between standard and intensive SBP were ≥0.05 except SBP (<italic>P</italic>=0.03) in the ACCORD BP standard glycemia arm and white race (<italic>P</italic>=0.01) in the ACCORD BP intensive glycemia arm.</p>
                  </fn>
                  <fn id="jah33491-note-0004">
                    <label>b</label>
                    <p>Clinical atherosclerotic disease was defined in ACCORD as one or more of myocardial infarction, stroke, angina, coronary artery bypass grafting, percutaneous coronary intervention, or other revascularization procedure. Clinical atherosclerotic disease was defined in SPRINT as ≥1 of myocardial infarction, acute coronary syndrome, coronary revascularization, carotid revascularization, peripheral artery disease with revascularization, &gt;50% stenosis of coronary/carotid/lower extremity artery; or abdominal aortic aneurysm ≥5 mm.</p>
                  </fn>
                </table-wrap-foot>
              </table-wrap>
              <p>The intervention lowered SBP in SPRINT and ACCORD BP with similar average differences in SBP between the 2 SBP treatment groups in SPRINT, the ACCORD BP standard glycemia arm, and the ACCORD BP intensive glycemia arm (Figure <xref rid="jah33491-sup-0001" ref-type="supplementary-material">S2</xref>).</p>
              <p>Mean durations of follow‐up in SPRINT and ACCORD BP were 3.22±0.85 and 4.95±1.19 years, respectively.</p>
              <sec id="jah33491-sec-0018">
                <title>Intensive SBP Lowering and the Risk of CVD Events and All‐Cause Mortality During the Entire Follow‐up in Both Studies</title>
                <p>Cumulative incidences of the composite CVD end points (Figure <xref rid="jah33491-fig-0001" ref-type="fig">1</xref>A–<xref rid="jah33491-fig-0001" ref-type="fig">1</xref>D) and all‐cause mortality (Figure <xref rid="jah33491-fig-0001" ref-type="fig">1</xref>E–<xref rid="jah33491-fig-0001" ref-type="fig">1</xref>H) were lower in the intensive SBP group compared with the standard SBP group in SPRINT and in the ACCORD BP standard glycemia arm but not in the ACCORD BP intensive glycemia arm. HRs for the composite CVD end point in the intensive versus standard SBP groups in SPRINT (HR: 0.75; 95% CI, 0.64–0.89) and the ACCORD BP standard glycemia arm (HR: 0.77; 95% CI, 0.63–0.95) were virtually identical, with an interaction <italic>P</italic>=0.87 (Figure <xref rid="jah33491-fig-0002" ref-type="fig">2</xref>A). In contrast, the HR for the groups with intensive versus standard SBP goals in the ACCORD BP intensive glycemia arm (HR 1.04, 95% CI 0.83–1.29) was significantly different (interaction <italic>P</italic>=0.023) from that noted in SPRINT (Figure <xref rid="jah33491-fig-0002" ref-type="fig">2</xref>A).</p>
                <fig fig-type="Figure" xml:lang="en" id="jah33491-fig-0001" orientation="portrait" position="float">
                  <label>Figure 1</label>
                  <caption>
                    <p>Cumulative incidence of composite <styled-content style="fixed-case">CVD</styled-content> end point (A–D) and all‐cause mortality (E–H) in intensive and standard <styled-content style="fixed-case">SBP</styled-content> groups. A, Composite <styled-content style="fixed-case">CVD</styled-content> end point in <styled-content style="fixed-case">SPRINT</styled-content>. B, Composite <styled-content style="fixed-case">CVD</styled-content> end point in <styled-content style="fixed-case">ACCORD BP</styled-content> standard glycemia arm. C, Composite <styled-content style="fixed-case">CVD</styled-content> end point in <styled-content style="fixed-case">ACCORD BP</styled-content> intensive glycemia arm. D, Composite <styled-content style="fixed-case">CVD</styled-content> end point in <styled-content style="fixed-case">ACCORD BP</styled-content> combined glycemia arms. E, All‐cause mortality in <styled-content style="fixed-case">SPRINT</styled-content>. F, All‐cause mortality in <styled-content style="fixed-case">ACCORD BP</styled-content> standard glycemia arm. G, All‐cause mortality in <styled-content style="fixed-case">ACCORD BP</styled-content> intensive glycemia arm. H, All‐cause mortality in <styled-content style="fixed-case">ACCORD BP</styled-content> combined glycemia arms. <styled-content style="fixed-case">ACCORD BP</styled-content> indicates Action to Control Cardiovascular Risk in Diabetes Blood Pressure; <styled-content style="fixed-case">CVD</styled-content>, cardiovascular disease; SBP, systolic blood pressure; <styled-content style="fixed-case">SPRINT</styled-content>, Systolic Blood Pressure Intervention Trial.</p>
                  </caption>
                  <graphic id="nlm-graphic-1" xlink:href="JAH3-7-e009326-g001"/>
                </fig>
                <fig fig-type="Figure" xml:lang="en" id="jah33491-fig-0002" orientation="portrait" position="float">
                  <label>Figure 2</label>
                  <caption>
                    <p>Effects of intensive <styled-content style="fixed-case">SBP</styled-content> control on the composite <styled-content style="fixed-case">CVD</styled-content> end point (A) and all‐cause mortality (B) in <styled-content style="fixed-case">SPRINT</styled-content> and <styled-content style="fixed-case">ACCORD BP</styled-content>. <styled-content style="fixed-case">ACCORD BP</styled-content> indicates Action to Control Cardiovascular Risk in Diabetes Blood Pressure; CI, confidence interval; <styled-content style="fixed-case">CVD</styled-content>, cardiovascular disease; <styled-content style="fixed-case">SBP</styled-content>, systolic blood pressure; <styled-content style="fixed-case">SPRINT</styled-content>, Systolic Blood Pressure Intervention Trial.</p>
                  </caption>
                  <graphic id="nlm-graphic-3" xlink:href="JAH3-7-e009326-g002"/>
                </fig>
                <p>All‐cause mortality HRs for the SPRINT intensive versus standard SBP groups (HR: 0.73; 95% CI, 0.60–0.90) and ACCORD BP standard glycemia arm (HR: 0.85; 95% CI, 0.61–1.19) were also similar, with an interaction <italic>P</italic>=0.46 (Figure <xref rid="jah33491-fig-0002" ref-type="fig">2</xref>B). In contrast, the HR for all‐cause mortality with intensive SBP lowering in the ACCORD BP intensive glycemia arm (HR: 1.34; 95% CI, 0.98–1.85) was significantly different (interaction <italic>P</italic>=0.002) from that in SPRINT (Figure <xref rid="jah33491-fig-0002" ref-type="fig">2</xref>B).</p>
                <p>In sensitivity analyses, when the ACCORD BP–protocol‐defined primary composite CVD end point (excluding heart failure and unstable angina) was used in ACCORD BP, the HRs for the intensive versus standard SBP comparisons were similar to those presented using the SPRINT‐like definition for the CVD outcome (Figure <xref rid="jah33491-sup-0001" ref-type="supplementary-material">S3</xref>).</p>
              </sec>
              <sec id="jah33491-sec-0019">
                <title>CVD Events and All‐Cause Mortality in the Combined Glycemia Arms in ACCORD BP</title>
                <p>The cumulative incidence of CVD events (Figure <xref rid="jah33491-fig-0001" ref-type="fig">1</xref>D) and all‐cause mortality (Figure <xref rid="jah33491-fig-0001" ref-type="fig">1</xref>H) in the combined glycemia arms in ACCORD BP reflected the summation of the effects of intensive SBP intervention on the cumulative incidence of CVD events in the standard and intensive glycemia arms (Figure <xref rid="jah33491-fig-0001" ref-type="fig">1</xref>B, <xref rid="jah33491-fig-0001" ref-type="fig">1</xref>C, <xref rid="jah33491-fig-0001" ref-type="fig">1</xref>F, and <xref rid="jah33491-fig-0001" ref-type="fig">1</xref>G). Similarly, the HRs for composite CVD end point and all‐cause mortality with intensive SBP lowering in the combined glycemia arms reflected the summation of the HRs for these events within each glycemia arm (Figure <xref rid="jah33491-fig-0002" ref-type="fig">2</xref>A and <xref rid="jah33491-fig-0002" ref-type="fig">2</xref>B).</p>
              </sec>
              <sec id="jah33491-sec-0020">
                <title>Effects of Intensive SBP Lowering on the Composite CVD End Point and All‐Cause Mortality Before and After Discontinuation of the Glycemia Intervention in the Intensive Glycemia Arm of ACCORD BP</title>
                <p>Incidence of the CVD composite end point and all‐cause deaths in the intensive and standard SBP groups before and after discontinuation of the glycemia intervention within the intensive glycemia arm of ACCORD BP are depicted in Figure <xref rid="jah33491-fig-0003" ref-type="fig">3</xref>. In a time‐dependent Cox regression (Table <xref rid="jah33491-tbl-0002" ref-type="table">2</xref>) performed in participants randomized to the intensive glycemia arm of ACCORD BP, the HR for the effects of intensive SBP lowering was 1.15 (95% CI, 0.90–1.46) on the glycemia intervention and 0.64 (95% CI, 0.38–1.10) after the intensive glycemia intervention was discontinued (interaction <italic>P</italic>=0.052). Similar results were obtained for all‐cause mortality, with HRs of 1.67 (95% CI, 1.13–2.45) before and 0.79 (95% CI, 0.44–1.44) after discontinuation of the intensive glycemia intervention (interaction <italic>P</italic>=0.041). In sensitivity analyses, results were similar when CVD events and all‐cause deaths in the first 14 months during intensive glycemia intervention were compared with CVD events and all‐cause deaths in the first 14 months after discontinuation of the intensive glycemia intervention (Figure <xref rid="jah33491-sup-0001" ref-type="supplementary-material">S4</xref>).</p>
                <fig fig-type="Figure" xml:lang="en" id="jah33491-fig-0003" orientation="portrait" position="float">
                  <label>Figure 3</label>
                  <caption>
                    <p>Cumulative incidence of the composite <styled-content style="fixed-case">CVD</styled-content> end point and all‐cause mortality in the intensive and standard <styled-content style="fixed-case">SBP</styled-content> groups before and after intensive glycemia intervention was discontinued in the <styled-content style="fixed-case">ACCORD BP</styled-content> intensive glycemia arm. A, Composite <styled-content style="fixed-case">CVD</styled-content> end point before intensive glycemia intervention was discontinued. B, Composite <styled-content style="fixed-case">CVD</styled-content> end point after intensive glycemia intervention was discontinued. C, All‐cause mortality before intensive glycemia intervention was discontinued. D, All‐cause mortality after intensive glycemia intervention was discontinued. Because the entire duration of the study is presented and the duration before intensive glycemia intervention was discontinued was much longer than the duration after intensive glycemia intervention was discontinued, the <italic>x‐</italic> and <italic>y</italic>‐axes scales are different for the before and after panels. Please see Figure <xref rid="jah33491-sup-0001" ref-type="supplementary-material">S3</xref> for graphic depiction of incidence of events during the first 14 months after randomization and the 14 months after discontinuation of the glycemia intervention. <styled-content style="fixed-case">ACCORD BP</styled-content> indicates Action to Control Cardiovascular Risk in Diabetes Blood Pressure; <styled-content style="fixed-case">CVD</styled-content>, cardiovascular disease; <styled-content style="fixed-case">SBP</styled-content>, systolic blood pressure.</p>
                  </caption>
                  <graphic id="nlm-graphic-5" xlink:href="JAH3-7-e009326-g003"/>
                </fig>
                <table-wrap id="jah33491-tbl-0002" xml:lang="en" orientation="portrait" position="float">
                  <label>Table 2</label>
                  <caption>
                    <p>Effects of Intensive SBP Lowering on the Composite CVD End Point and All‐Cause Mortality During and After Intensive Glycemia Intervention Was Discontinued Within the Intensive Glycemia Arm in ACCORD BP in Time‐Dependent Cox Regression Models</p>
                  </caption>
                  <table frame="hsides" rules="groups">
                    <col style="border-right:solid 1px #000000" span="1"/>
                    <col style="border-right:solid 1px #000000" span="1"/>
                    <col style="border-right:solid 1px #000000" span="1"/>
                    <col style="border-right:solid 1px #000000" span="1"/>
                    <thead valign="top">
                      <tr style="border-bottom:solid 1px #000000">
                        <th align="left" rowspan="2" valign="top" colspan="1">Outcome</th>
                        <th align="left" colspan="2" style="border-bottom:solid 1px #000000" valign="top" rowspan="1">HR (95% CI) and <italic>P</italic> Value for Intensive vs Standard SBP</th>
                        <th align="left" rowspan="2" valign="top" colspan="1">Interaction <italic>P</italic> Value</th>
                      </tr>
                      <tr style="border-bottom:solid 1px #000000">
                        <th align="left" valign="top" rowspan="1" colspan="1">During Glycemia Intervention</th>
                        <th align="left" valign="top" rowspan="1" colspan="1">Postglycemia Intervention</th>
                      </tr>
                    </thead>
                    <tbody>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Composite CVD end point</td>
                        <td align="left" rowspan="1" colspan="1">1.15 (0.90–1.46), <italic>P</italic>=0.259</td>
                        <td align="left" rowspan="1" colspan="1">0.64 (0.38–1.10), <italic>P</italic>=0.105</td>
                        <td align="left" rowspan="1" colspan="1">0.052</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">All‐cause mortality</td>
                        <td align="left" rowspan="1" colspan="1">1.67 (1.13–2.45), <italic>P</italic>=0.010</td>
                        <td align="left" rowspan="1" colspan="1">0.79 (0.44–1.44), <italic>P</italic>=0.445</td>
                        <td align="left" rowspan="1" colspan="1">0.041</td>
                      </tr>
                    </tbody>
                  </table>
                  <table-wrap-foot>
                    <fn id="jah33491-note-0005">
                      <p>ACCORD BP indicates Action to Control Cardiovascular Risk in Diabetes Blood Pressure; CI, confidence interval; CVD, cardiovascular disease; HR, hazard ratio; SBP, systolic blood pressure.</p>
                    </fn>
                  </table-wrap-foot>
                </table-wrap>
              </sec>
              <sec id="jah33491-sec-0021">
                <title>Comparison of the Effects of Intensive SBP Lowering on the Risk of CVD Events and All‐Cause Mortality in SPRINT and in ACCORD BP Before Discontinuation of the Intensive Glycemia Intervention</title>
                <p>The HRs of intensive SBP lowering for the composite CVD end point or all‐cause mortality in SPRINT were not different from those in the standard glycemia arm of ACCORD BP before discontinuation of the intensive glycemia intervention (Figure <xref rid="jah33491-fig-0004" ref-type="fig">4</xref>A and <xref rid="jah33491-fig-0004" ref-type="fig">4</xref>B). The HRs of intensive SBP lowering for the composite CVD end point and all‐cause mortality during the glycemia intervention in the intensive glycemia arm were significantly different from SPRINT (interaction <italic>P</italic>=0.006 for the composite CVD end point and <italic>P</italic>&lt;0.001 for all‐cause mortality).</p>
                <fig fig-type="Figure" xml:lang="en" id="jah33491-fig-0004" orientation="portrait" position="float">
                  <label>Figure 4</label>
                  <caption>
                    <p>Effects of intensive <styled-content style="fixed-case">SBP</styled-content> control on the composite <styled-content style="fixed-case">CVD</styled-content> end point (A) and all‐cause mortality (B) in <styled-content style="fixed-case">SPRINT</styled-content> and before the glycemia intervention was discontinued in <styled-content style="fixed-case">ACCORD BP</styled-content>. <styled-content style="fixed-case">ACCORD BP</styled-content> indicates Action to Control Cardiovascular Risk in Diabetes Blood Pressure; CI, confidence interval; <styled-content style="fixed-case">CVD</styled-content>, cardiovascular disease; <styled-content style="fixed-case">SBP</styled-content>, systolic blood pressure; <styled-content style="fixed-case">SPRINT</styled-content>, Systolic Blood Pressure Intervention Trial.</p>
                  </caption>
                  <graphic id="nlm-graphic-7" xlink:href="JAH3-7-e009326-g004"/>
                </fig>
              </sec>
              <sec id="jah33491-sec-0022">
                <title>Comparison of the Effects of Intensive SBP Lowering on the Risk of Individual Components of the Primary Composite CVD End Point in SPRINT and in ACCORD BP Before Discontinuation of the Intensive Glycemia Intervention</title>
                <p>In general, intensive SBP lowering was associated with reductions in CVD death (Figure <xref rid="jah33491-fig-0005" ref-type="fig">5</xref>), congestive heart failure (Figure <xref rid="jah33491-fig-0006" ref-type="fig">6</xref>), and myocardial infarction/coronary heart disease events (Figure <xref rid="jah33491-fig-0007" ref-type="fig">7</xref>) in SPRINT and in the ACCORD BP standard glycemia arm but was associated with increases in these events in the ACCORD BP intensive glycemia arm. In contrast, intensive SBP lowering was associated with reductions in stroke across SPRINT and both ACCORD BP glycemia arms (Figure <xref rid="jah33491-fig-0008" ref-type="fig">8</xref>).</p>
                <fig fig-type="Figure" xml:lang="en" id="jah33491-fig-0005" orientation="portrait" position="float">
                  <label>Figure 5</label>
                  <caption>
                    <p>Effects of intensive <styled-content style="fixed-case">SBP</styled-content> control on <styled-content style="fixed-case">CVD</styled-content> death in <styled-content style="fixed-case">SPRINT</styled-content> and before the glycemia intervention was discontinued in <styled-content style="fixed-case">ACCORD BP</styled-content>. <styled-content style="fixed-case">ACCORD BP</styled-content> indicates Action to Control Cardiovascular Risk in Diabetes Blood Pressure; CI, confidence interval; <styled-content style="fixed-case">CVD</styled-content>, cardiovascular disease; <styled-content style="fixed-case">SBP</styled-content>, systolic blood pressure; <styled-content style="fixed-case">SPRINT</styled-content>, Systolic Blood Pressure Intervention Trial.</p>
                  </caption>
                  <graphic id="nlm-graphic-9" xlink:href="JAH3-7-e009326-g005"/>
                </fig>
                <fig fig-type="Figure" xml:lang="en" id="jah33491-fig-0006" orientation="portrait" position="float">
                  <label>Figure 6</label>
                  <caption>
                    <p>Effects of intensive <styled-content style="fixed-case">SBP</styled-content> control on heart failure in <styled-content style="fixed-case">SPRINT</styled-content> and before the glycemia intervention was discontinued in <styled-content style="fixed-case">ACCORD BP</styled-content>. <styled-content style="fixed-case">ACCORD BP</styled-content> indicates Action to Control Cardiovascular Risk in Diabetes Blood Pressure; CI, confidence interval; <styled-content style="fixed-case">SBP</styled-content>, systolic blood pressure; <styled-content style="fixed-case">SPRINT</styled-content>, Systolic Blood Pressure Intervention Trial.</p>
                  </caption>
                  <graphic id="nlm-graphic-11" xlink:href="JAH3-7-e009326-g006"/>
                </fig>
                <fig fig-type="Figure" xml:lang="en" id="jah33491-fig-0007" orientation="portrait" position="float">
                  <label>Figure 7</label>
                  <caption>
                    <p>Effects of intensive <styled-content style="fixed-case">SBP</styled-content> control on myocardial infarction/coronary heart disease events in <styled-content style="fixed-case">SPRINT</styled-content> and before the glycemia intervention was discontinued in <styled-content style="fixed-case">ACCORD BP</styled-content>. <styled-content style="fixed-case">ACCORD BP</styled-content> indicates Action to Control Cardiovascular Risk in Diabetes Blood Pressure; CI, confidence interval; <styled-content style="fixed-case">SBP</styled-content>, systolic blood pressure; <styled-content style="fixed-case">SPRINT</styled-content>, Systolic Blood Pressure Intervention Trial.</p>
                  </caption>
                  <graphic id="nlm-graphic-13" xlink:href="JAH3-7-e009326-g007"/>
                </fig>
                <fig fig-type="Figure" xml:lang="en" id="jah33491-fig-0008" orientation="portrait" position="float">
                  <label>Figure 8</label>
                  <caption>
                    <p>Effects of intensive <styled-content style="fixed-case">SBP</styled-content> control on stroke in <styled-content style="fixed-case">SPRINT</styled-content> and before the glycemia intervention was discontinued in <styled-content style="fixed-case">ACCORD BP</styled-content>. <styled-content style="fixed-case">ACCORD BP</styled-content> indicates Action to Control Cardiovascular Risk in Diabetes Blood Pressure; CI, confidence interval; <styled-content style="fixed-case">SBP</styled-content>, systolic blood pressure; <styled-content style="fixed-case">SPRINT</styled-content>, Systolic Blood Pressure Intervention Trial.</p>
                  </caption>
                  <graphic id="nlm-graphic-15" xlink:href="JAH3-7-e009326-g008"/>
                </fig>
              </sec>
            </sec>
            <sec id="jah33491-sec-0023">
              <title>Discussion</title>
              <p>The results of these post hoc comparisons of the effects of intensive SBP lowering on CVD events and all‐cause mortality between SPRINT and ACCORD BP indicate that the effects of intensive SBP lowering were similar in SPRINT and the ACCORD BP standard glycemia arm. In contrast, the effects of intensive SBP lowering were significantly different between SPRINT and the ACCORD BP intensive glycemia arm. Furthermore, the apparent increased risk of CVD events and all‐cause mortality with intensive SBP lowering during the intensive glycemia intervention appeared to dissipate after discontinuation of the glycemia intervention.</p>
              <p>The reasons for the lack of statistical significance between the primary composite CVD end point in the ACCORD BP trial intensive versus standard SBP treatment arms<xref rid="jah33491-bib-0009" ref-type="ref">9</xref> remain widely debated, given the highly significant findings observed in SPRINT.<xref rid="jah33491-bib-0011" ref-type="ref">11</xref> A participant‐level pooled meta‐analysis of SPRINT and ACCORD BP participants suggested that in the combined cohort, intensive SBP lowering decreased the risk of CVD events.<xref rid="jah33491-bib-0019" ref-type="ref">19</xref> These results, however, were primarily driven by the SPRINT data.<xref rid="jah33491-bib-0019" ref-type="ref">19</xref> Differences in blood pressure measurement techniques,<xref rid="jah33491-bib-0020" ref-type="ref">20</xref> differences in the achieved SBP separations,<xref rid="jah33491-bib-0021" ref-type="ref">21</xref> and differences in selection criteria<xref rid="jah33491-bib-0022" ref-type="ref">22</xref> have also been proposed as potential explanations. Although these explanations are possibilities, other potential explanations merit consideration. Perhaps the most widely cited reason for the discordant results is a lack of statistical power in ACCORD BP.<xref rid="jah33491-bib-0012" ref-type="ref">12</xref>, <xref rid="jah33491-bib-0019" ref-type="ref">19</xref> However, the total numbers of CVD and death events were actually higher in ACCORD BP because of a higher event rate and longer duration of follow‐up. Consequently, a lack of statistical power in ACCORD BP compared with SPRINT does not appear to provide a sufficient explanation for the divergent results.</p>
              <p>An alternative explanation is that there was an interaction between the intensive glycemia intervention and the intensive SBP lowering intervention in ACCORD BP that may have masked the potential beneficial effects of the SBP intervention. This hypothesis is supported by 2 aspects of the results of the current analysis. First, intensive SBP lowering appeared to reduce the risk of CVD events and all‐cause mortality in the standard glycemia arm but not in the intensive glycemia arm of the ACCORD BP trial. In an analysis of the combined glycemia arms, these competing effects resulted in a nonsignificant decrease in CVD event risk and a nonsignificant increase in all‐cause mortality risk. Second, as suggested by Table <xref rid="jah33491-tbl-0002" ref-type="table">2</xref> and Figure <xref rid="jah33491-fig-0003" ref-type="fig">3</xref>, apparent deleterious effects of intensive SBP lowering in the intensive glycemia arm of ACCORD BP appeared to dissipate after discontinuation of the intensive glycemia intervention.</p>
              <p>Biological plausibility exists for an interaction between intensive glycemic control and intensive SBP control. Compared with patients without diabetes mellitus, adults with T2DM have diminished myocardial glucose extraction and utilization despite similar levels of plasma insulin and higher plasma glucose levels.<xref rid="jah33491-bib-0023" ref-type="ref">23</xref> This may limit the ability of the myocardium in patients with T2DM to withstand ischemia and may contribute to the increased CVD morbidity and mortality in these patients.<xref rid="jah33491-bib-0023" ref-type="ref">23</xref> Therefore, in the setting of intensive glycemic control in T2DM, intensive SBP lowering compared with standard SBP control might result in worse CVD outcomes. This premise is supported by analysis of the individual components of the primary composite CVD end point; intensive SBP lowering appeared to increase cardiac events but not stroke. Consequently, the myocardium might be uniquely susceptible to intensive SBP lowering in the setting of intensive glycemic control.</p>
              <p>A previous ACCORD BP report noted that, compared with the combined standard SBP and standard glycemia group, intensive management of either SBP or glycemia alone improved major CVD outcomes.<xref rid="jah33491-bib-0013" ref-type="ref">13</xref> We noted similar findings for CVD event rates during the entire period of follow‐up. The major difference between the current and previous reports is that the current analysis used SPRINT as the external reference point and compared CVD events and all‐cause mortality in the standard and intensive glycemia treatment arms separately. In addition, we examined the effects of intensive SBP lowering before and after discontinuation of the intensive glycemia intervention within the intensive glycemia arm of ACCORD BP. Because intensive glycemia treatment is no longer recommended because of its increased all‐cause mortality risk,<xref rid="jah33491-bib-0024" ref-type="ref">24</xref> we believe that the benefits from intensive SBP lowering in the standard glycemia arm of ACCORD BP are clinically relevant for the management of hypertension in patients with T2DM. The current analysis supports intensive SBP lowering for CVD protection in patients with T2DM on standard glycemic control.</p>
              <p>A limitation of the current study is that it was based on post hoc analyses. The ACCORD BP trial was analyzed using a prespecified factorial design in which the analysis of the effect of the intensive SBP intervention was based on an overall intensive versus standard SBP comparison in which the results were aggregated across both the intensive and standard glycemic control groups. This type of analysis assumes minimal or no interaction between the treatments being studied. Nonetheless, our post hoc analysis cannot fully exclude the possibility that the interactions between the SBP and glycemic control interventions in ACCORD BP were due to chance.</p>
              <p>In conclusion, results of the current analyses support the possibility that intensive SBP lowering offers similar beneficial effects in patients without diabetes mellitus and in patients with T2DM on standard glycemic control. There appears to be an interaction between intensive SBP lowering and intensive glycemic control that resulted in increased CVD events and all‐cause mortality and that dissipated after discontinuation of the intensive glycemia intervention. This interaction between intensive SBP lowering and intensive glycemic control is the likely explanation for the discordant results noted between SPRINT and the combined glycemia arms of ACCORD BP. Taken together, these randomized comparisons support intensive SBP lowering in patients without diabetes mellitus and in patients with T2DM on standard glycemic control, as suggested by recent guidelines.<xref rid="jah33491-bib-0008" ref-type="ref">8</xref>
</p>
            </sec>
            <sec id="jah33491-sec-0025">
              <title>Sources of Funding</title>
              <p>Statistical analyses and preparation of this article were supported by grants from the National Institute of Diabetes and Digestive and Kidney Diseases (R01 DK091437 and R21 DK106574) and the University of Utah Study Design and Biostatistics Center (funded in part from the Public Health Services research grant numbers UL1‐RR025764 and C06‐RR11234 from the National Center for Research Resources). SPRINT (Systolic Blood Pressure Intervention Trial) is funded with federal funds from the National Institutes of Health, including the National Heart, Lung, and Blood Institute, the National Institute of Diabetes and Digestive and Kidney Diseases, the National Institute on Aging, and the National Institute of Neurological Disorders and Stroke under contract nos. HHSN268200900040C, HHSN268200900046C, HHSN268200900047C, HHSN268200900048C, HHSN268200900049C, and interagency agreement no. A‐HL‐13‐002‐001. It was also supported in part with resources and use of facilities through the US Department of Veterans Affairs. We also acknowledge the support from the following Clinical and Translational Science Awards funded by the National Center for Advancing Translational Science: Case Western Reserve University: UL1TR000439, Ohio State University: UL1RR025755, University of Pennsylvania: UL1RR024134 &amp; UL1TR000003, Boston University: UL1RR025771, Stanford University: UL1TR000093, Tufts University: UL1RR025752, UL1TR000073 &amp; UL1TR001064, University of Illinois: UL1TR000050, University of Pittsburgh: UL1TR000005, University of Texas Southwestern: 9U54TR000017‐06, University of Utah: UL1TR000105‐05, Vanderbilt University: UL1 TR000445, George Washington University: UL1TR000075, University of California, Davis: UL1 TR000002, University of Florida: UL1 TR000064, University of Michigan: UL1TR000433, Tulane University: P30GM103337 Centers of Biomedical Research Excellence Award National Institute of General Medical Sciences.</p>
            </sec>
            <sec id="jah33491-sec-0026">
              <title>Disclosures</title>
              <p>None.</p>
            </sec>
            <sec sec-type="supplementary-material">
              <title>Supporting information</title>
              <supplementary-material content-type="local-data" id="jah33491-sup-0001">
                <caption>
                  <p><bold>Table S1.</bold> Comparison of Baseline Characteristics Between SPRINT (Systolic Blood Pressure Intervention Trial) and ACCORD BP (Action to Control Cardiovascular Risk in Diabetes Blood Pressure)</p>
                  <p><bold>Figure S1.</bold> CONSORT flow diagram for SPRINT (Systolic Blood Pressure Intervention Trial) and ACCORD BP (Action to Control Cardiovascular Risk in Diabetes Blood Pressure) participants.</p>
                  <p><bold>Figure S2.</bold> Follow‐up mean systolic blood pressure (SBP; 95% confidence interval) by SBP groups in SPRINT (Systolic Blood Pressure Intervention Trial) and ACCORD BP (Action to Control Cardiovascular Risk in Diabetes Blood Pressure) standard and intensive glycemia arms.</p>
                  <p><bold>Figure S3.</bold> Effects of intensive systolic blood pressure control on SPRINT (Systolic Blood Pressure Intervention Trial) protocol‐defined primary cardiovascular disease (CVD) end point in SPRINT and ACCORD BP (Action to Control Cardiovascular Risk in Diabetes Blood Pressure) protocol‐defined primary CVD end point in ACCORD BP.</p>
                  <p><bold>Figure S4.</bold> Cumulative incidence of composite cardiovascular disease end point and all‐cause mortality in intensive and standard systolic blood pressure groups in the first 14 months during intensive glycemia intervention and in the first 14 months after discontinuation of the intensive glycemia intervention.</p>
                </caption>
                <media xlink:href="JAH3-7-e009326-s001.pdf">
                  <caption>
                    <p>Click here for additional data file.</p>
                  </caption>
                </media>
              </supplementary-material>
            </sec>
          </body>
          <back>
            <ack id="jah33491-sec-0024">
              <title>Acknowledgments</title>
              <p>All authors are SPRINT (Systolic Blood Pressure Intervention Trial) investigators. Ambrosius, Cutler, Fine, and Cushman are also ACCORD BP (Action to Control Cardiovascular Risk in Diabetes Blood Pressure) investigators. This article was prepared using SPRINT data obtained from the National Heart, Lung, and Blood Institute Biologic Specimen and Data Repository Information Coordinating Center. The views expressed in this article are those of the authors and do not represent the official position of the National Institutes of Health (NIH), the US Department of Veterans Affairs, the US government, or the SPRINT Research Group or the ACCORD Study Group. This article was approved by the SPRINT Publications and Presentations Committee. The SPRINT investigators acknowledge the contribution of study medications (azilsartan and azilsartan combined with chlorthalidone) from Takeda Pharmaceuticals International, Inc. All components of the SPRINT study protocol were designed and implemented by the SPRINT investigators. The investigative team collected, analyzed, and interpreted the data. All aspects of article writing and revision were carried out by the coauthors.</p>
            </ack>
            <ref-list content-type="cited-references" id="jah33491-bibl-0001">
              <title>References</title>
              <ref id="jah33491-bib-0001">
                <label>1</label>
                <mixed-citation publication-type="journal" id="jah33491-cit-0001"><string-name><surname>Law</surname><given-names>MR</given-names></string-name>, <string-name><surname>Morris</surname><given-names>JK</given-names></string-name>, <string-name><surname>Wald</surname><given-names>NJ</given-names></string-name>. <article-title>Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta‐analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies</article-title>. <source xml:lang="en">BMJ</source>. <year>2009</year>;<volume>338</volume>:<fpage>b1665</fpage>.<pub-id pub-id-type="pmid">19454737</pub-id></mixed-citation>
              </ref>
              <ref id="jah33491-bib-0002">
                <label>2</label>
                <mixed-citation publication-type="journal" id="jah33491-cit-0002"><string-name><surname>Xie</surname><given-names>X</given-names></string-name>, <string-name><surname>Atkins</surname><given-names>E</given-names></string-name>, <string-name><surname>Lv</surname><given-names>J</given-names></string-name>, <string-name><surname>Bennett</surname><given-names>A</given-names></string-name>, <string-name><surname>Neal</surname><given-names>B</given-names></string-name>, <string-name><surname>Ninomiya</surname><given-names>T</given-names></string-name>, <string-name><surname>Woodward</surname><given-names>M</given-names></string-name>, <string-name><surname>MacMahon</surname><given-names>S</given-names></string-name>, <string-name><surname>Turnbull</surname><given-names>F</given-names></string-name>, <string-name><surname>Hillis</surname><given-names>GS</given-names></string-name>, <string-name><surname>Chalmers</surname><given-names>J</given-names></string-name>, <string-name><surname>Mant</surname><given-names>J</given-names></string-name>, <string-name><surname>Salam</surname><given-names>A</given-names></string-name>, <string-name><surname>Rahimi</surname><given-names>K</given-names></string-name>, <string-name><surname>Perkovic</surname><given-names>V</given-names></string-name>, <string-name><surname>Rodgers</surname><given-names>A</given-names></string-name>. <article-title>Effects of intensive blood pressure lowering on cardiovascular and renal outcomes: updated systematic review and meta‐analysis</article-title>. <source xml:lang="en">Lancet</source>. <year>2016</year>;<volume>387</volume>:<fpage>435</fpage>–<lpage>443</lpage>.<pub-id pub-id-type="pmid">26559744</pub-id></mixed-citation>
              </ref>
              <ref id="jah33491-bib-0003">
                <label>3</label>
                <mixed-citation publication-type="journal" id="jah33491-cit-0003"><string-name><surname>James</surname><given-names>PA</given-names></string-name>, <string-name><surname>Oparil</surname><given-names>S</given-names></string-name>, <string-name><surname>Carter</surname><given-names>BL</given-names></string-name>, <string-name><surname>Cushman</surname><given-names>WC</given-names></string-name>, <string-name><surname>Dennison‐Himmelfarb</surname><given-names>C</given-names></string-name>, <string-name><surname>Handler</surname><given-names>J</given-names></string-name>, <string-name><surname>Lackland</surname><given-names>DT</given-names></string-name>, <string-name><surname>LeFevre</surname><given-names>ML</given-names></string-name>, <string-name><surname>MacKenzie</surname><given-names>TD</given-names></string-name>, <string-name><surname>Ogedegbe</surname><given-names>O</given-names></string-name>, <string-name><surname>Smith</surname><given-names>SC</given-names><suffix>Jr</suffix></string-name>, <string-name><surname>Svetkey</surname><given-names>LP</given-names></string-name>, <string-name><surname>Taler</surname><given-names>SJ</given-names></string-name>, <string-name><surname>Townsend</surname><given-names>RR</given-names></string-name>, <string-name><surname>Wright</surname><given-names>JT</given-names><suffix>Jr</suffix></string-name>, <string-name><surname>Narva</surname><given-names>AS</given-names></string-name>, <string-name><surname>Ortiz</surname><given-names>E</given-names></string-name>. <article-title>2014 evidence‐based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8)</article-title>. <source xml:lang="en">JAMA</source>. <year>2014</year>;<volume>311</volume>:<fpage>507</fpage>–<lpage>520</lpage>.<pub-id pub-id-type="pmid">24352797</pub-id></mixed-citation>
              </ref>
              <ref id="jah33491-bib-0004">
                <label>4</label>
                <mixed-citation publication-type="journal" id="jah33491-cit-0004"><string-name><surname>Wright</surname><given-names>JT</given-names></string-name>, <string-name><surname>Fine</surname><given-names>LJ</given-names></string-name>, <string-name><surname>Lackland</surname><given-names>DT</given-names></string-name>, <string-name><surname>Ogedegbe</surname><given-names>G</given-names></string-name>, <string-name><surname>Dennison Himmelfarb</surname><given-names>CR</given-names></string-name>. <article-title>Evidence supporting a systolic blood pressure goal of less than 150 mm Hg in patients aged 60 years or older: the minority view systolic blood pressure goal for patients aged 60 years or older</article-title>. <source xml:lang="en">Ann Intern Med</source>. <year>2014</year>;<volume>160</volume>:<fpage>499</fpage>–<lpage>503</lpage>.<pub-id pub-id-type="pmid">24424788</pub-id></mixed-citation>
              </ref>
              <ref id="jah33491-bib-0005">
                <label>5</label>
                <mixed-citation publication-type="journal" id="jah33491-cit-0005"><string-name><surname>Ettehad</surname><given-names>D</given-names></string-name>, <string-name><surname>Emdin</surname><given-names>CA</given-names></string-name>, <string-name><surname>Kiran</surname><given-names>A</given-names></string-name>, <string-name><surname>Anderson</surname><given-names>SG</given-names></string-name>, <string-name><surname>Callender</surname><given-names>T</given-names></string-name>, <string-name><surname>Emberson</surname><given-names>J</given-names></string-name>, <string-name><surname>Chalmers</surname><given-names>J</given-names></string-name>, <string-name><surname>Rodgers</surname><given-names>A</given-names></string-name>, <string-name><surname>Rahimi</surname><given-names>K</given-names></string-name>. <article-title>Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta‐analysis</article-title>. <source xml:lang="en">Lancet</source>. <year>2016</year>;<volume>387</volume>:<fpage>957</fpage>–<lpage>967</lpage>.<pub-id pub-id-type="pmid">26724178</pub-id></mixed-citation>
              </ref>
              <ref id="jah33491-bib-0006">
                <label>6</label>
                <mixed-citation publication-type="journal" id="jah33491-cit-0006"><string-name><surname>Bundy</surname><given-names>JD</given-names></string-name>, <string-name><surname>Li</surname><given-names>C</given-names></string-name>, <string-name><surname>Stuchlik</surname><given-names>P</given-names></string-name>, <string-name><surname>Bu</surname><given-names>X</given-names></string-name>, <string-name><surname>Kelly</surname><given-names>TN</given-names></string-name>, <string-name><surname>Mills</surname><given-names>KT</given-names></string-name>, <string-name><surname>He</surname><given-names>H</given-names></string-name>, <string-name><surname>Chen</surname><given-names>J</given-names></string-name>, <string-name><surname>Whelton</surname><given-names>PK</given-names></string-name>, <string-name><surname>He</surname><given-names>J</given-names></string-name>. <article-title>Systolic blood pressure reduction and risk of cardiovascular disease and mortality: a systematic review and network meta‐analysis</article-title>. <source xml:lang="en">JAMA Cardiol</source>. <year>2017</year>;<volume>2</volume>:<fpage>775</fpage>–<lpage>781</lpage>.<pub-id pub-id-type="pmid">28564682</pub-id></mixed-citation>
              </ref>
              <ref id="jah33491-bib-0007">
                <label>7</label>
                <mixed-citation publication-type="journal" id="jah33491-cit-0007"><string-name><surname>Brunstrom</surname><given-names>M</given-names></string-name>, <string-name><surname>Carlberg</surname><given-names>B</given-names></string-name>. <article-title>Effect of antihypertensive treatment at different blood pressure levels in patients with diabetes mellitus: systematic review and meta‐analyses</article-title>. <source xml:lang="en">BMJ</source>. <year>2016</year>;<volume>352</volume>:<fpage>i717</fpage>.<pub-id pub-id-type="pmid">26920333</pub-id></mixed-citation>
              </ref>
              <ref id="jah33491-bib-0008">
                <label>8</label>
                <mixed-citation publication-type="journal" id="jah33491-cit-0008"><string-name><surname>Whelton</surname><given-names>PK</given-names></string-name>, <string-name><surname>Carey</surname><given-names>RM</given-names></string-name>, <string-name><surname>Aronow</surname><given-names>WS</given-names></string-name>, <string-name><surname>Casey</surname><given-names>DE</given-names><suffix>Jr</suffix></string-name>, <string-name><surname>Collins</surname><given-names>KJ</given-names></string-name>, <string-name><surname>Dennison Himmelfarb</surname><given-names>C</given-names></string-name>, <string-name><surname>DePalma</surname><given-names>SM</given-names></string-name>, <string-name><surname>Gidding</surname><given-names>S</given-names></string-name>, <string-name><surname>Jamerson</surname><given-names>KA</given-names></string-name>, <string-name><surname>Jones</surname><given-names>DW</given-names></string-name>, <string-name><surname>MacLaughlin</surname><given-names>EJ</given-names></string-name>, <string-name><surname>Muntner</surname><given-names>P</given-names></string-name>, <string-name><surname>Ovbiagele</surname><given-names>B</given-names></string-name>, <string-name><surname>Smith</surname><given-names>SC</given-names><suffix>Jr</suffix></string-name>, <string-name><surname>Spencer</surname><given-names>CC</given-names></string-name>, <string-name><surname>Stafford</surname><given-names>RS</given-names></string-name>, <string-name><surname>Taler</surname><given-names>SJ</given-names></string-name>, <string-name><surname>Thomas</surname><given-names>RJ</given-names></string-name>, <string-name><surname>Williams</surname><given-names>KA</given-names><suffix>Sr</suffix></string-name>, <string-name><surname>Williamson</surname><given-names>JD</given-names></string-name>, <string-name><surname>Wright</surname><given-names>JT</given-names><suffix>Jr</suffix></string-name>. <article-title>2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines</article-title>. <source xml:lang="en">Hypertension</source>. <year>2018</year>;<volume>71</volume>:<fpage>1269</fpage>–<lpage>1324</lpage>.<pub-id pub-id-type="pmid">29133354</pub-id></mixed-citation>
              </ref>
              <ref id="jah33491-bib-0009">
                <label>9</label>
                <mixed-citation publication-type="journal" id="jah33491-cit-0009"><collab collab-type="authors">ACCORD Study Group</collab>
, <string-name><surname>Cushman</surname><given-names>WC</given-names></string-name>, <string-name><surname>Evans</surname><given-names>GW</given-names></string-name>, <string-name><surname>Byington</surname><given-names>RP</given-names></string-name>, <string-name><surname>Goff</surname><given-names>DC</given-names><suffix>Jr</suffix></string-name>, <string-name><surname>Grimm</surname><given-names>RH</given-names><suffix>Jr</suffix></string-name>, <string-name><surname>Cutler</surname><given-names>JA</given-names></string-name>, <string-name><surname>Simons‐Morton</surname><given-names>DG</given-names></string-name>, <string-name><surname>Basile</surname><given-names>JN</given-names></string-name>, <string-name><surname>Corson</surname><given-names>MA</given-names></string-name>, <string-name><surname>Probstfield</surname><given-names>JL</given-names></string-name>, <string-name><surname>Katz</surname><given-names>L</given-names></string-name>, <string-name><surname>Peterson</surname><given-names>KA</given-names></string-name>, <string-name><surname>Friedewald</surname><given-names>WT</given-names></string-name>, <string-name><surname>Buse</surname><given-names>JB</given-names></string-name>, <string-name><surname>Bigger</surname><given-names>JT</given-names></string-name>, <string-name><surname>Gerstein</surname><given-names>HC</given-names></string-name>, <string-name><surname>Ismail‐Beigi</surname><given-names>F</given-names></string-name>. <article-title>Effects of intensive blood‐pressure control in type 2 diabetes mellitus</article-title>. <source xml:lang="en">N Engl J Med</source>. <year>2010</year>;<volume>362</volume>:<fpage>1575</fpage>–<lpage>1585</lpage>.<pub-id pub-id-type="pmid">20228401</pub-id></mixed-citation>
              </ref>
              <ref id="jah33491-bib-0010">
                <label>10</label>
                <mixed-citation publication-type="journal" id="jah33491-cit-0010"><string-name><surname>Ambrosius</surname><given-names>WT</given-names></string-name>, <string-name><surname>Sink</surname><given-names>KM</given-names></string-name>, <string-name><surname>Foy</surname><given-names>CG</given-names></string-name>, <string-name><surname>Berlowitz</surname><given-names>DR</given-names></string-name>, <string-name><surname>Cheung</surname><given-names>AK</given-names></string-name>, <string-name><surname>Cushman</surname><given-names>WC</given-names></string-name>, <string-name><surname>Fine</surname><given-names>LJ</given-names></string-name>, <string-name><surname>Goff</surname><given-names>DC</given-names><suffix>Jr</suffix></string-name>, <string-name><surname>Johnson</surname><given-names>KC</given-names></string-name>, <string-name><surname>Killeen</surname><given-names>AA</given-names></string-name>, <string-name><surname>Lewis</surname><given-names>CE</given-names></string-name>, <string-name><surname>Oparil</surname><given-names>S</given-names></string-name>, <string-name><surname>Reboussin</surname><given-names>DM</given-names></string-name>, <string-name><surname>Rocco</surname><given-names>MV</given-names></string-name>, <string-name><surname>Snyder</surname><given-names>JK</given-names></string-name>, <string-name><surname>Williamson</surname><given-names>JD</given-names></string-name>, <string-name><surname>Wright</surname><given-names>JT</given-names><suffix>Jr</suffix></string-name>, <string-name><surname>Whelton</surname><given-names>PK</given-names></string-name>. <article-title>The design and rationale of a multicenter clinical trial comparing two strategies for control of systolic blood pressure: the Systolic Blood Pressure Intervention Trial (SPRINT)</article-title>. <source xml:lang="en">Clin Trials</source>. <year>2014</year>;<volume>11</volume>:<fpage>532</fpage>–<lpage>546</lpage>.<pub-id pub-id-type="pmid">24902920</pub-id></mixed-citation>
              </ref>
              <ref id="jah33491-bib-0011">
                <label>11</label>
                <mixed-citation publication-type="journal" id="jah33491-cit-0011"><collab collab-type="authors">SPRINT Research Group</collab>
, <string-name><surname>Wright</surname><given-names>JT</given-names><suffix>Jr</suffix></string-name>, <string-name><surname>Williamson</surname><given-names>JD</given-names></string-name>, <string-name><surname>Whelton</surname><given-names>PK</given-names></string-name>, <string-name><surname>Snyder</surname><given-names>JK</given-names></string-name>, <string-name><surname>Sink</surname><given-names>KM</given-names></string-name>, <string-name><surname>Rocco</surname><given-names>MV</given-names></string-name>, <string-name><surname>Reboussin</surname><given-names>DM</given-names></string-name>, <string-name><surname>Rahman</surname><given-names>M</given-names></string-name>, <string-name><surname>Oparil</surname><given-names>S</given-names></string-name>, <string-name><surname>Lewis</surname><given-names>CE</given-names></string-name>, <string-name><surname>Kimmel</surname><given-names>PL</given-names></string-name>, <string-name><surname>Johnson</surname><given-names>KC</given-names></string-name>, <string-name><surname>Goff</surname><given-names>DC</given-names><suffix>Jr</suffix></string-name>, <string-name><surname>Fine</surname><given-names>LJ</given-names></string-name>, <string-name><surname>Cutler</surname><given-names>JA</given-names></string-name>, <string-name><surname>Cushman</surname><given-names>WC</given-names></string-name>, <string-name><surname>Cheung</surname><given-names>AK</given-names></string-name>, <string-name><surname>Ambrosius</surname><given-names>WT</given-names></string-name>. <article-title>A randomized trial of intensive versus standard blood‐pressure control</article-title>. <source xml:lang="en">N Engl J Med</source>. <year>2015</year>;<volume>373</volume>:<fpage>2103</fpage>–<lpage>2116</lpage>.<pub-id pub-id-type="pmid">26551272</pub-id></mixed-citation>
              </ref>
              <ref id="jah33491-bib-0012">
                <label>12</label>
                <mixed-citation publication-type="journal" id="jah33491-cit-0012"><string-name><surname>Perkovic</surname><given-names>V</given-names></string-name>, <string-name><surname>Rodgers</surname><given-names>A</given-names></string-name>. <article-title>Redefining blood‐pressure targets—SPRINT starts the marathon</article-title>. <source xml:lang="en">N Engl J Med</source>. <year>2015</year>;<volume>373</volume>:<fpage>2175</fpage>–<lpage>2178</lpage>.<pub-id pub-id-type="pmid">26551394</pub-id></mixed-citation>
              </ref>
              <ref id="jah33491-bib-0013">
                <label>13</label>
                <mixed-citation publication-type="journal" id="jah33491-cit-0013"><string-name><surname>Margolis</surname><given-names>KL</given-names></string-name>, <string-name><surname>O'Connor</surname><given-names>PJ</given-names></string-name>, <string-name><surname>Morgan</surname><given-names>TM</given-names></string-name>, <string-name><surname>Buse</surname><given-names>JB</given-names></string-name>, <string-name><surname>Cohen</surname><given-names>RM</given-names></string-name>, <string-name><surname>Cushman</surname><given-names>WC</given-names></string-name>, <string-name><surname>Cutler</surname><given-names>JA</given-names></string-name>, <string-name><surname>Evans</surname><given-names>GW</given-names></string-name>, <string-name><surname>Gerstein</surname><given-names>HC</given-names></string-name>, <string-name><surname>Grimm</surname><given-names>RH</given-names></string-name>, <string-name><surname>Lipkin</surname><given-names>EW</given-names></string-name>, <string-name><surname>Narayan</surname><given-names>KMV</given-names></string-name>, <string-name><surname>Riddle</surname><given-names>MC</given-names></string-name>, <string-name><surname>Sood</surname><given-names>A</given-names></string-name>, <string-name><surname>Goff</surname><given-names>DC</given-names></string-name>. <article-title>Outcomes of combined cardiovascular risk factor management strategies in type 2 diabetes: the ACCORD randomized trial</article-title>. <source xml:lang="en">Diabetes Care</source>. <year>2014</year>;<volume>37</volume>:<fpage>1721</fpage>–<lpage>1728</lpage>.<pub-id pub-id-type="pmid">24595629</pub-id></mixed-citation>
              </ref>
              <ref id="jah33491-bib-0014">
                <label>14</label>
                <mixed-citation publication-type="miscellaneous" id="jah33491-cit-0014"><collab collab-type="authors">National Heart, Lung, and Blood Institute</collab>
. <article-title>Biologic specimen and data repository information coordinating center</article-title>. Available at: <ext-link ext-link-type="uri" xlink:href="https://biolincc.nhlbi.nih.gov/home/">https://biolincc.nhlbi.nih.gov/home/</ext-link>. Accessed August 2, 2018.</mixed-citation>
              </ref>
              <ref id="jah33491-bib-0015">
                <label>15</label>
                <mixed-citation publication-type="miscellaneous" id="jah33491-cit-0015"><collab collab-type="authors">National Heart, Lung, and Blood Institute</collab>
. <article-title>Action to Control Cardiovascular Risk in Diabetes (ACCORD) protocol. BioLINCC</article-title>. August 13, <year>2013</year> Available at: <ext-link ext-link-type="uri" xlink:href="https://biolincc.nhlbi.nih.gov/media/studies/accord/Protocol.pdf">https://biolincc.nhlbi.nih.gov/media/studies/accord/Protocol.pdf</ext-link>. Accessed August 2, 2018.</mixed-citation>
              </ref>
              <ref id="jah33491-bib-0016">
                <label>16</label>
                <mixed-citation publication-type="journal" id="jah33491-cit-0016"><collab collab-type="authors">Action to Control Cardiovascular Risk in Diabetes Study G</collab>
, <string-name><surname>Gerstein</surname><given-names>HC</given-names></string-name>, <string-name><surname>Miller</surname><given-names>ME</given-names></string-name>, <string-name><surname>Byington</surname><given-names>RP</given-names></string-name>, <string-name><surname>Goff</surname><given-names>DC</given-names><suffix>Jr</suffix></string-name>, <string-name><surname>Bigger</surname><given-names>JT</given-names></string-name>, <string-name><surname>Buse</surname><given-names>JB</given-names></string-name>, <string-name><surname>Cushman</surname><given-names>WC</given-names></string-name>, <string-name><surname>Genuth</surname><given-names>S</given-names></string-name>, <string-name><surname>Ismail‐Beigi</surname><given-names>F</given-names></string-name>, <string-name><surname>Grimm</surname><given-names>RH</given-names><suffix>Jr</suffix></string-name>, <string-name><surname>Probstfield</surname><given-names>JL</given-names></string-name>, <string-name><surname>Simons‐Morton</surname><given-names>DG</given-names></string-name>, <string-name><surname>Friedewald</surname><given-names>WT</given-names></string-name>. <article-title>Effects of intensive glucose lowering in type 2 diabetes</article-title>. <source xml:lang="en">N Engl J Med</source>. <year>2008</year>;<volume>358</volume>:<fpage>2545</fpage>–<lpage>2559</lpage>.<pub-id pub-id-type="pmid">18539917</pub-id></mixed-citation>
              </ref>
              <ref id="jah33491-bib-0017">
                <label>17</label>
                <mixed-citation publication-type="journal" id="jah33491-cit-0017"><collab collab-type="authors">ACCORD Study Group</collab>
, <string-name><surname>Ginsberg</surname><given-names>HN</given-names></string-name>, <string-name><surname>Elam</surname><given-names>MB</given-names></string-name>, <string-name><surname>Lovato</surname><given-names>LC</given-names></string-name>, <string-name><surname>Crouse</surname><given-names>JR</given-names><suffix>III</suffix></string-name>, <string-name><surname>Leiter</surname><given-names>LA</given-names></string-name>, <string-name><surname>Linz</surname><given-names>P</given-names></string-name>, <string-name><surname>Friedewald</surname><given-names>WT</given-names></string-name>, <string-name><surname>Buse</surname><given-names>JB</given-names></string-name>, <string-name><surname>Gerstein</surname><given-names>HC</given-names></string-name>, <string-name><surname>Probstfield</surname><given-names>J</given-names></string-name>, <string-name><surname>Grimm</surname><given-names>RH</given-names></string-name>, <string-name><surname>Ismail‐Beigi</surname><given-names>F</given-names></string-name>, <string-name><surname>Bigger</surname><given-names>JT</given-names></string-name>, <string-name><surname>Goff</surname><given-names>DC</given-names><suffix>Jr</suffix></string-name>, <string-name><surname>Cushman</surname><given-names>WC</given-names></string-name>, <string-name><surname>Simons‐Morton</surname><given-names>DG</given-names></string-name>, <string-name><surname>Byington</surname><given-names>RP</given-names></string-name>. <article-title>Effects of combination lipid therapy in type 2 diabetes mellitus</article-title>. <source xml:lang="en">N Engl J Med</source>. <year>2010</year>;<volume>362</volume>:<fpage>1563</fpage>–<lpage>1574</lpage>.<pub-id pub-id-type="pmid">20228404</pub-id></mixed-citation>
              </ref>
              <ref id="jah33491-bib-0018">
                <label>18</label>
                <mixed-citation publication-type="miscellaneous" id="jah33491-cit-0018"><collab collab-type="authors">National Heart, Lung, and Blood Institute</collab>
. <article-title>Systolic Blood Pressure Intervention Protocol Version 4.0. BioLINCC</article-title>. August 22, <year>2016</year> Available at: <ext-link ext-link-type="uri" xlink:href="https://biolincc.nhlbi.nih.gov/media/studies/sprint_pop/Protocol.pdf">https://biolincc.nhlbi.nih.gov/media/studies/sprint_pop/Protocol.pdf</ext-link>. Accessed August 2, 2018.</mixed-citation>
              </ref>
              <ref id="jah33491-bib-0019">
                <label>19</label>
                <mixed-citation publication-type="journal" id="jah33491-cit-0019"><string-name><surname>Brouwer</surname><given-names>TF</given-names></string-name>, <string-name><surname>Vehmeijer</surname><given-names>JT</given-names></string-name>, <string-name><surname>Kalkman</surname><given-names>DN</given-names></string-name>, <string-name><surname>Berger</surname><given-names>WR</given-names></string-name>, <string-name><surname>van den Born</surname><given-names>B‐JH</given-names></string-name>, <string-name><surname>Peters</surname><given-names>RJ</given-names></string-name>, <string-name><surname>Knops</surname><given-names>RE</given-names></string-name>. <article-title>Intensive blood pressure lowering in patients with and patients without type 2 diabetes: a pooled analysis from two randomized trials</article-title>. <source xml:lang="en">Diabetes Care</source>. <year>2018</year>;<volume>41</volume>:<fpage>1142</fpage>–<lpage>1148</lpage>.<pub-id pub-id-type="pmid">29212825</pub-id></mixed-citation>
              </ref>
              <ref id="jah33491-bib-0020">
                <label>20</label>
                <mixed-citation publication-type="journal" id="jah33491-cit-0020"><string-name><surname>Kjeldsen</surname><given-names>SE</given-names></string-name>, <string-name><surname>Lund‐Johansen</surname><given-names>P</given-names></string-name>, <string-name><surname>Nilsson</surname><given-names>PM</given-names></string-name>, <string-name><surname>Mancia</surname><given-names>G</given-names></string-name>. <article-title>Unattended blood pressure measurements in the systolic blood pressure intervention trial: implications for entry and achieved blood pressure values compared with other trials</article-title>. <source xml:lang="en">Hypertension</source>. <year>2016</year>;<volume>67</volume>:<fpage>808</fpage>–<lpage>812</lpage>.<pub-id pub-id-type="pmid">27001295</pub-id></mixed-citation>
              </ref>
              <ref id="jah33491-bib-0021">
                <label>21</label>
                <mixed-citation publication-type="journal" id="jah33491-cit-0021"><string-name><surname>Huang</surname><given-names>C</given-names></string-name>, <string-name><surname>Dhruva</surname><given-names>SS</given-names></string-name>, <string-name><surname>Coppi</surname><given-names>AC</given-names></string-name>, <string-name><surname>Warner</surname><given-names>F</given-names></string-name>, <string-name><surname>Li</surname><given-names>SX</given-names></string-name>, <string-name><surname>Lin</surname><given-names>H</given-names></string-name>, <string-name><surname>Nasir</surname><given-names>K</given-names></string-name>, <string-name><surname>Krumholz</surname><given-names>HM</given-names></string-name>. <article-title>Systolic blood pressure response in SPRINT (Systolic Blood Pressure Intervention Trial) and ACCORD (Action to Control Cardiovascular Risk in Diabetes): a possible explanation for discordant trial results</article-title>. <source xml:lang="en">J Am Heart Assoc</source>. <year>2017</year>;<volume>6</volume>:<fpage>e007509</fpage> DOI: <pub-id pub-id-type="doi">10.1161/JAHA.117.007509</pub-id>.<pub-id pub-id-type="pmid">29133522</pub-id></mixed-citation>
              </ref>
              <ref id="jah33491-bib-0022">
                <label>22</label>
                <mixed-citation publication-type="journal" id="jah33491-cit-0022"><string-name><surname>Buckley</surname><given-names>LF</given-names></string-name>, <string-name><surname>Dixon</surname><given-names>DL</given-names></string-name>, <string-name><surname>Wohlford</surname><given-names>GF</given-names><suffix>IV</suffix></string-name>, <string-name><surname>Wijesinghe</surname><given-names>DS</given-names></string-name>, <string-name><surname>Baker</surname><given-names>WL</given-names></string-name>, <string-name><surname>Van Tassell</surname><given-names>BW</given-names></string-name>. <article-title>Intensive versus standard blood pressure control in SPRINT‐eligible participants of ACCORD‐BP</article-title>. <source xml:lang="en">Diabetes Care</source>. <year>2017</year>;<volume>40</volume>:<fpage>1733</fpage>–<lpage>1738</lpage>.<pub-id pub-id-type="pmid">28947569</pub-id></mixed-citation>
              </ref>
              <ref id="jah33491-bib-0023">
                <label>23</label>
                <mixed-citation publication-type="journal" id="jah33491-cit-0023"><string-name><surname>Dutka</surname><given-names>DP</given-names></string-name>, <string-name><surname>Pitt</surname><given-names>M</given-names></string-name>, <string-name><surname>Pagano</surname><given-names>D</given-names></string-name>, <string-name><surname>Mongillo</surname><given-names>M</given-names></string-name>, <string-name><surname>Gathercole</surname><given-names>D</given-names></string-name>, <string-name><surname>Bonser</surname><given-names>RS</given-names></string-name>, <string-name><surname>Camici</surname><given-names>PG</given-names></string-name>. <article-title>Myocardial glucose transport and utilization in patients with type 2 diabetes mellitus, left ventricular dysfunction, and coronary artery disease</article-title>. <source xml:lang="en">J Am Coll Cardiol</source>. <year>2006</year>;<volume>48</volume>:<fpage>2225</fpage>–<lpage>2231</lpage>.<pub-id pub-id-type="pmid">17161251</pub-id></mixed-citation>
              </ref>
              <ref id="jah33491-bib-0024">
                <label>24</label>
                <mixed-citation publication-type="miscellaneous" id="jah33491-cit-0024"><collab collab-type="authors">American Diabetes Association: Standards of Medical Care in Diabetes‐2017</collab>
. <article-title>Diabetes care</article-title>. December 15, <year>2016</year> Available at: <ext-link ext-link-type="uri" xlink:href="http://care.diabetesjournals.org/content/diacare/suppl/2016/12/15/40.Supplement_1.DC1/DC_40_S1_final.pdf">http://care.diabetesjournals.org/content/diacare/suppl/2016/12/15/40.Supplement_1.DC1/DC_40_S1_final.pdf</ext-link>. Accessed August 2, 2018.</mixed-citation>
              </ref>
            </ref-list>
          </back>
        </article>
      </metadata>
    </record>
  </GetRecord>
</OAI-PMH>
